By Plainview Herald, Plainview Herald

Starting on Dec. 2, the Lubbock radar operated by the NOAAs National Weather Service will be down to implement a major upgrade.

Technicians will operate on KLBB WSR-88D to refurbish and replace the pedestal, one of the most critical components of the radar, which is necessary for antenna rotation and position to capture date in all directions.

The components are extremely heavy and will require the radome to be removed by crane and replaced when the work is completed.

The radar and pedestal were designed to last 25 years and this radar has exceeded its lifespan. The upgrade is necessary to keep the radar functioning for another 20 years or more.

The pedestal refurbishment is the third major project of the NEXRAD Service Life Extension Program, a series of upgrades that will keep the nations radars viable into the 2030s. NOAAs National Weather Service, the United States Air Force and the Federal Aviation Administration are investing $135 million in the eight-year program.

The first project was the installation of the new signal processor and the second project was the refurbishment of the transmitter. The fourth project will be the refurbishment of the equipment shelters. The Service Life Extension Program will be complete in 2023.

During the downtime, adjacent radars will be available. These include: KMAF Midland, KAMA Amarillo, KFDR Frederick, OK (Altus AFB), KFDX Clovis, NM (Cannon AFB), and KABI Abilene (Dyess AFB).

For direct access to any of these surrounding radar sites, visit https://radar.weather.gov/.

The KLBB WSR-88D is part of a network of 159 operational radars. The Radar Operations Center in Norman, Oklahoma, provides lifecycle management and support for all WSR-88Ds.

The National Weather Service in Lubbock can be found at weather.gov/Lubbock.

Link:
Lubbock weather radar to be down for 2 weeks - Plainview Daily Herald

Recommendation and review posted by Bethany Smith

25 November 2020

by Nicholas Fiorenza

Armasuisse, the Swiss Federal Office for Defence Procurement, has awarded a contract to BAE Systems Hgglunds (BSH) for the life extension of the Swiss Armys 186 CV9030s, which Switzerland designates as the Schtzenpanzer (Infantry Fighting Vehicle, IFV) 2000, BSH announced in a news release on 18 November. The life extension aims to keep the IFV in service until 2040.

Armasuisse has awarded a contract to BSH for the life extension of the Swiss Armys 186 Schtzenpanzer 2000 IFVs. (DDPS)

BSH said the life-extension programme would modernise the Schtzenpanzer 2000s optical, electrical, and electronic components and include the installation of active damping technology to reduce wear and tear and through-life repair costs, as well as increase the IFVs cross-country speed and comfort.

The Federal Department of Defence, Civil Protection and Sport (DDPS) said on its website that the vehicles chassis would be reinforced and the following components would be replaced: computer systems and displays, vehicle information systems, the camera system, infrared camera, and electricity generator. The life-extension programme would not increase the Schtzenpanzer 2000s capabilities, according to the DDPS, but the vehicles will be fitted with a 360 surveillance system, which BSH said would increase the vehicles situational awareness, combat effectiveness, and survivability by allowing safer route planning and quicker targeting. Installation of a new electronics architecture would support the adaptation of the IFV to future developments in technology, the company added.

Already a Janes subscriber? Read the full article via theClient LoginInterested in subscribing, see What we do

Share

Armasuisse, the Swiss Federal Office for Defence Procurement, has awarded a contract to BAE Systems ...

Original post:
Switzerland extends life of CV90s - Jane's

Recommendation and review posted by Bethany Smith

Overview for Oral Probiotics Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The Oral Probiotics market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Oral Probiotics market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Oral Probiotics market. The report focuses on well-known providers in the global Oral Probiotics industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Oral Probiotics Industry will develop is also analyzed in detail in Chapter 1.7 of the report., In Chapter 2.4, we analyzed industry trends in the context of COVID-19., In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets., In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries., In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Download PDF Sample of Oral Probiotics Market report @ https://www.arcognizance.com/enquiry-sample/1314283

Key players in the global Oral Probiotics market covered in Chapter 4:, Lallemand, TheraBreath, Life Extension, Now Foods, Jarrow Formulas, ProBiora Health, Hyperbiotics, Bifodan, Bluestone Pharma, BioGaia, Oragenics

In Chapter 11 and 13.3, on the basis of types, the Oral Probiotics market from 2015 to 2026 is primarily split into:, Powder, Chewable tablets, Others

In Chapter 12 and 13.4, on the basis of applications, the Oral Probiotics market from 2015 to 2026 covers:, Child, Adult

[emailprotected] https://www.arcognizance.com/discount/1314283

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

Years considered for this report:, Historical Years: 2015-2019, Base Year: 2019, Estimated Year: 2020, Forecast Period: 2020-2026

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Oral Probiotics Market

Chapter Four: Players Profiles

Chapter Five: Global Oral Probiotics Market Analysis by Regions

[emailprotected]https://www.arcognizance.com/purchase/1314283

Chapter Six: North America Oral Probiotics Market Analysis by Countries

Chapter Seven: Europe Oral Probiotics Market Analysis by Countries

Chapter Eight: Asia-Pacific Oral Probiotics Market Analysis by Countries

Chapter Nine: Middle East and Africa Oral Probiotics Market Analysis by Countries

Chapter Ten: South America Oral Probiotics Market Analysis by Countries

Chapter Eleven: Global Oral Probiotics Market Segment by Types

Chapter Twelve: Global Oral Probiotics Market Segment by Applications12.1 Global Oral Probiotics Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Oral Probiotics Sales and Market Share by Applications (2015-2020)12.1.2 Global Oral Probiotics Revenue and Market Share by Applications (2015-2020)12.2 Child Sales, Revenue and Growth Rate (2015-2020)12.3 Adult Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Oral Probiotics Market Forecast by Regions (2020-2026) continue

List of tablesList of Tables and FiguresTable Global Oral Probiotics Market Size Growth Rate by Type (2020-2026)Figure Global Oral Probiotics Market Share by Type in 2019 & 2026Figure Powder FeaturesFigure Chewable tablets FeaturesFigure Others FeaturesTable Global Oral Probiotics Market Size Growth by Application (2020-2026)Figure Global Oral Probiotics Market Share by Application in 2019 & 2026Figure Child DescriptionFigure Adult DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Oral Probiotics Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Oral Probiotics Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Oral ProbioticsFigure Production Process of Oral ProbioticsFigure Manufacturing Cost Structure of Oral ProbioticsFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Lallemand ProfileTable Lallemand Production, Value, Price, Gross Margin 2015-2020Table TheraBreath ProfileTable TheraBreath Production, Value, Price, Gross Margin 2015-2020Table Life Extension ProfileTable Life Extension Production, Value, Price, Gross Margin 2015-2020Table Now Foods ProfileTable Now Foods Production, Value, Price, Gross Margin 2015-2020Table Jarrow Formulas ProfileTable Jarrow Formulas Production, Value, Price, Gross Margin 2015-2020Table ProBiora Health ProfileTable ProBiora Health Production, Value, Price, Gross Margin 2015-2020Table Hyperbiotics ProfileTable Hyperbiotics Production, Value, Price, Gross Margin 2015-2020Table Bifodan ProfileTable Bifodan Production, Value, Price, Gross Margin 2015-2020Table Bluestone Pharma ProfileTable Bluestone Pharma Production, Value, Price, Gross Margin 2015-2020Table BioGaia ProfileTable BioGaia Production, Value, Price, Gross Margin 2015-2020Table Oragenics ProfileTable Oragenics Production, Value, Price, Gross Margin 2015-2020Figure Global Oral Probiotics Sales and Growth Rate (2015-2020)Figure Global Oral Probiotics Revenue ($) and Growth (2015-2020)Table Global Oral Probiotics Sales by Regions (2015-2020)Table Global Oral Probiotics Sales Market Share by Regions (2015-2020)Table Global Oral Probiotics Revenue ($) by Regions (2015-2020)Table Global Oral Probiotics Revenue Market Share by Regions (2015-2020)Table Global Oral Probiotics Revenue Market Share by Regions in 2015Table Global Oral Probiotics Revenue Market Share by Regions in 2019Figure North America Oral Probiotics Sales and Growth Rate (2015-2020)Figure Europe Oral Probiotics Sales and Growth Rate (2015-2020)Figure Asia-Pacific Oral Probiotics Sales and Growth Rate (2015-2020)Figure Middle East and Africa Oral Probiotics Sales and Growth Rate (2015-2020)Figure South America Oral Probiotics Sales and Growth Rate (2015-2020)Figure North America Oral Probiotics Revenue ($) and Growth (2015-2020)Table North America Oral Probiotics Sales by Countries (2015-2020)Table North America Oral Probiotics Sales Market Share by Countries (2015-2020)Figure North America Oral Probiotics Sales Market Share by Countries in 2015Figure North America Oral Probiotics Sales Market Share by Countries in 2019Table North America Oral Probiotics Revenue ($) by Countries (2015-2020)Table North America Oral Probiotics Revenue Market Share by Countries (2015-2020)Figure North America Oral Probiotics Revenue Market Share by Countries in 2015Figure North America Oral Probiotics Revenue Market Share by Countries in 2019Figure United States Oral Probiotics Sales and Growth Rate (2015-2020)Figure Canada Oral Probiotics Sales and Growth Rate (2015-2020)Figure Mexico Oral Probiotics Sales and Growth (2015-2020)Figure Europe Oral Probiotics Revenue ($) Growth (2015-2020)Table Europe Oral Probiotics Sales by Countries (2015-2020)Table Europe Oral Probiotics Sales Market Share by Countries (2015-2020)Figure Europe Oral Probiotics Sales Market Share by Countries in 2015Figure Europe Oral Probiotics Sales Market Share by Countries in 2019Table Europe Oral Probiotics Revenue ($) by Countries (2015-2020)Table Europe Oral Probiotics Revenue Market Share by Countries (2015-2020)Figure Europe Oral Probiotics Revenue Market Share by Countries in 2015Figure Europe Oral Probiotics Revenue Market Share by Countries in 2019Figure Germany Oral Probiotics Sales and Growth Rate (2015-2020)Figure UK Oral Probiotics Sales and Growth Rate (2015-2020)Figure France Oral Probiotics Sales and Growth Rate (2015-2020)Figure Italy Oral Probiotics Sales and Growth Rate (2015-2020)Figure Spain Oral Probiotics Sales and Growth Rate (2015-2020)Figure Russia Oral Probiotics Sales and Growth Rate (2015-2020)Figure Asia-Pacific Oral Probiotics Revenue ($) and Growth (2015-2020)Table Asia-Pacific Oral Probiotics Sales by Countries (2015-2020)Table Asia-Pacific Oral Probiotics Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Oral Probiotics Sales Market Share by Countries in 2015Figure Asia-Pacific Oral Probiotics Sales Market Share by Countries in 2019Table Asia-Pacific Oral Probiotics Revenue ($) by Countries (2015-2020)Table Asia-Pacific Oral Probiotics Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Oral Probiotics Revenue Market Share by Countries in 2015Figure Asia-Pacific Oral Probiotics Revenue Market Share by Countries in 2019Figure China Oral Probiotics Sales and Growth Rate (2015-2020)Figure Japan Oral Probiotics Sales and Growth Rate (2015-2020)Figure South Korea Oral Probiotics Sales and Growth Rate (2015-2020)Figure Australia Oral Probiotics Sales and Growth Rate (2015-2020)Figure India Oral Probiotics Sales and Growth Rate (2015-2020)Figure Southeast Asia Oral Probiotics Sales and Growth Rate (2015-2020)Figure Middle East and Africa Oral Probiotics Revenue ($) and Growth (2015-2020)continue

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

Follow this link:
Impact of COVID-19 on Oral Probiotics Market 2020 Industry Insight, Segment by Key Companies, Countries, Types, Applications and Forecast to 2026 -...

Recommendation and review posted by Bethany Smith

With the advancing electronics and semiconductors industry, the demand for cold plasma (CP) has been on the rise. While the demand for applications such as coating and finishing, surface treatment, adhesion, and etching, associated with printed circuit boards (PCBs) is soaring, the market for cold plasma is also expected to benefit from a slew of applications arising in other end use industries. Moreover, increasing applications in food safety will also push the market for cold plasma further, over the next few years. As depicted in a recent research report published by Persistence Market Research (PMR), the US$ 1.4 Bn global cold plasma market is presumed to observe stellar growth over an eight-year projection period. Between 2018 and 2026, the cold plasma market will possibly expand at a CAGR of 16.3%, as indicated by PMRs global cold plasma market report.

Get Sample Copy Of This [emailprotected] https://www.persistencemarketresearch.com/samples/17053

The potential applications of cold plasma technology traverse a wide range, including the extension of product shelf-life and environmental sustainability. Such applications have been attracting the scientific community towards cold plasma research, over the years. The CP technique has already been proven to be an economic and environment-friendly technology in the textile industry. Textile companies are increasingly adopting cold plasma technique in an effort to deliver improved textile finishing.

Cold Plasma Technology Soon to Transform Wound Treatment Space

While cold plasma applications in sterilization and disinfection are currently accounting for maximum revenue in the cold plasma market, rapidly emerging applications in wound healing and adhesion will reportedly create lucrative opportunities for stakeholders.

Coldplasmatech GmbH, a German company, is looking forward to introduce a novel CP technology that could potentially revolutionize the wound care treatment platform, especially in emergency rooms in hospitals. The CP technology involves a patch of cold plasma made of silicone (as a part of the wound dressing), which can be used in treatment of chronic wound infections with the help of UV radiations and ions. This technology is presumed to provide a high-tech, efficient alternative to antibiotics, considering its ability to accelerate the wound healing process. If the trials based on the application of the cold plasma technology in faster wound healing deliver convincing and viable results, industry experts predict that the CP technology could become a widespread method for treatment of chronic wounds and infection, in near future.

Request For [emailprotected] https://www.persistencemarketresearch.com/methodology/17053

Cold Plasma Technology to Win Preference over Conventional Processing Technologies

Among all end use industries generating demand for cold plasma, electronics and semiconductors are foreseen to reign supreme. Whereas, rising demand for cold plasma is expected to uplift the prospects for cold plasma in food processing and packaging, and plastics and polymers industries.

Advanced cold plasma technology is being widely used in the in-package decontamination of fresh foods. Shelf-life extension will also remain a key objective of fresh food industry participants, using cold plasma as a unit technology. With successful trials of the regulation of contaminants mediated by cold plasma, the applications of cold plasma in agriculture sector are expected to surge in near future. Additionally, research shows that it is possible to degrade the chemical residues of pesticides to relatively lesser toxic and safer structures, by using cold plasma. It also offers an excellent alternative to conventional fertilizers and pesticides.

You Can Checkout This Complete [emailprotected] https://www.persistencemarketresearch.com/checkout/17053

As far as the processed and packaged food industry is concerned, cold plasma has been proven to hold immense potential as a safe and eco-friendly alternative to traditionally used chemical processes. Moreover, it is considered as a novel non-thermal technology for processing of foods, especially fruits and vegetables, and poultry and meat prominently attributed to the non-thermal nature, versatile design, and economic pricing of cold plasma. Research findings also confirm that cold plasma treatment poses no or minimal impact on a products chemical, physical, sensory, and nutritional attributes. However, it still remains to be seen whether cold plasma processing will completely replace the traditionally used processing technologies, as the research outcome is still in the pipeline and demands more extensive research in order to reach its potential.

Explore Extensive Coverage of PMR`s

Chemicals and Nanomaterials Industry

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Merin JohnPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales [emailprotected]Website https://www.persistencemarketresearch.com

Read more:
Incremental Sales to Drive the Cold Plasma Market by 2026 - The Market Feed

Recommendation and review posted by Bethany Smith

It is normal for females to experience fluctuations in sexual desire throughout life. However, a substantial or total loss of interest in sex, or difficulty responding to stimulation, may indicate female sexual interest/arousal disorder (FSIAD).

FSIAD is a type of sexual dysfunction. A person with the condition may experience a lack of sexual desire, a lack of physical arousal, or both.

As with other types of sexual dysfunction, FSIAD can be distressing. It can affect a persons self-esteem, relationships, and overall well-being.

In this article, we explore FSIAD and its symptoms, causes, and treatments.

FSIAD describes a loss or significant reduction in sexual desire or physical arousal in females. It is a relatively new term that first appeared in the Diagnostic and Statistical Manual of Mental Health Disorders (DSM-5).

Previously, FSIAD was split into two separate disorders:

FSAD used to refer to a lack of lubrication and swelling in the female genitals, which researchers focused on as a cause for sexual dysfunction.

However, some experts argue that this is a flawed concept, as low levels of lubrication does not necessarily indicate female arousal, nor does it always prevent sex.

There is a close link between sexual desire and physical arousal. As a result, the DSM-5 combined the two conditions.

It is unclear how many people experience FSIAD specifically. However, sexual dysfunction is highly common in males and females.

A 2016 meta-analysis suggests that around 40.9% of premenopausal women worldwide experience at least one type of sexual dysfunction. Of those, 28% reported low sexual desire.

However, compared to some types of sexual dysfunction in males, such as erectile dysfunction, FSIAD is far less well-known.

According to the DSM-5, a person must have three of the following symptoms to have FSIAD:

They must also have:

In addition to this, people with FSIAD can experience symptoms in different ways. The condition may be:

Partners may notice that a person with FSIAD does not want to engage in sex most of the time and that they talk about it less, or not at all.

It is important to note that FSIAD is different from asexuality.

Asexuality is an umbrella term for sexual orientations that involve varying degrees of sexual and romantic attraction towards others. It is not a medical condition.

Some asexual people have lifelong preferences for nonsexual relationships. While a lifelong lack of interest in sex can occur due to sexual dysfunction, this is not always the case.

According to the DSM-5, for an FSIAD diagnosis to apply, a person must show signs of clinically significant distress about their lack of desire.

A person who identifies as asexual, does not feel distressed by it, and has no problem developing close relationships, does not meet the criteria for FSIAD.

Sexual desire and arousal are complex. Many factors influence the amount and type of sexual desire a person has and how their body responds to intimacy.

While a single cause is often difficult to identify, the DSM-5 notes that people with FSIAD often have other sexual or emotional difficulties, some of which are explored below.

A 2018 review found that relationship dissatisfaction was a risk factor for sexual dysfunction in females. This may be the result of communication problems, a lack of emotional intimacy, or unresolved conflict.

The mental and physical health of partners may also have an impact. If a person desires sex more often than their partner or partners, or they have sexual dysfunction themselves, this may influence the development of FSIAD.

A negative self-image, lack of confidence in ones body or appearance, and mood disorders are also associated with FSIAD.

Negative body image, or body dysmorphic disorder, may make the prospect of removing clothes or sexual activity stressful. Stress, anxiety, and depression can also reduce a persons desire to have sex.

However, it is important to note that low self-esteem, stress, and mental health conditions can occur as a result of FSIAD, and may not be the direct cause.

Some people with FSIAD have previously experienced emotional or sexual abuse. A 2020 study suggests that sexual trauma, such as childhood sexual abuse, can lead to shame surrounding sex, which may then contribute to sexual dysfunction.

Personal, cultural, and religious beliefs can play a role in FSIAD.

People who believe in traditional gender roles may feel they should not play an active role in sex or that they should not enjoy it. This may create feelings of shame surrounding sex.

If a person does not have much experience or knowledge about sex, they may have unrealistic ideas about what is normal in terms of sexual desire. They may also struggle to explain what they like or dislike, or be unaware of different sexual techniques.

It is important that people have access to quality sex education that normalizes sexual desire, and teaches that sex has a positive role in a persons well-being.

The 2018 review notes that sex education and feeling that sex is important in a relationship are both protective factors against sexual dysfunction.

Many people with FSIAD may also experience other types of sexual difficulties, such as:

Treating these conditions may help with improving a persons FSIAD symptoms.

Learn about the causes of pain during sex.

Other factors that may cause changes to a persons sexual desire and arousal include:

There are several ways to approach treatment for FSIAD. These include:

Talking with a sex therapist, psychotherapist, or counselor specializing in female sexual health can help someone identify factors contributing to their FSIAD.

A sex therapist or psychotherapist can help someone:

If relationship difficulties contribute to FSIAD, a therapist may also recommend relationship counseling sessions, where the persons partner also attends.

Medication options for FSIAD include Vyleesi (bremelanotide), which activates receptors in the brain that influence sexual behavior and desire.

Hormone therapy may help treat low sexual desire in people going through menopause or who have hormone imbalances.

These medications will not be appropriate for everyone. It is important to discuss the safety, interactions, and side effects of these treatments with a doctor before trying them.

If a persons sexual desire or physical response to sexual stimulation has changed since they developed a mental or physical health condition, or since they began taking a certain medication, this may be a factor.

A person can discuss the following options with a doctor:

If a person notices they have lower sexual desire than usual, or do not seem to respond to sexual stimulation as they used to, they can seek help from a physician or healthcare professional specializing in sexual function.

It can be difficult to talk about sexual dysfunction, but there is no shame in doing so. It is a medical condition, which can get better with treatment.

Being specific about any concerns or changes in desire or arousal will help a doctor advise on the next steps.

FSIAD is a type of sexual dysfunction that occurs when a persons sexual desire or arousal is much lower than usual. It can cause significant distress. However, sexual dysfunction is prevalent in females, and it is treatable.

Many factors may contribute to FSIAD, so a person may benefit from trying several treatment approaches. Options include individual therapy, trauma therapy, relationship counseling, or medication.

Visit link:
What is female arousal disorder? Symptoms and treatment - Medical News Today

Recommendation and review posted by Bethany Smith

ALBANY Monique and Fred Wilson are lovingly known as the King and Queen of Phoebe, Fred as the familiar friendly face who greets visitors to the hospital and gives them rides through the massive parking lot and Monique as, among other duties, the face-to-face coordinator for the regions Young Survivors Coalition.

Its fitting, then, for the thousands of hospital employees and patients whove been treated there that Monique Wilson has been honored as the tree-lighter for the Phoebe Foundations annual Lights of Love celebration. And while the annual heart-felt ceremony was altered to a virtual celebration this year in deference to the coronavirus pandemic, that does little to dampen the enthusiasm of the woman chosen to represent the cancer survivors as the tree-lighter.

Even though we pre-recorded the (tree-lighting) event as a safety precaution and will show the ceremony later, it was still very moving for me, Monique Wilson, who is the survivorship data coordinator at Phoebe, said. Even filming it ahead of time, I was very nervous at first. But it was such a beautiful ceremony even with the social distancing that I got caught up in it. Ill never forget it.

Wilson was selected as the tree-lighter for the Lights of Love celebration, which is sponsored annually by the Phoebe Foundation and raises funds for cancer-related projects, as a breast cancer survivor. She was diagnosed in June of 2016 and is today cancer-free.

My husband and I were coming back from a trip to New Jersey, when I felt something strange (in my breast), she said. When we got home to Georgia, I rechecked the spot, and it was still there. No one on either side of my family has ever had breast cancer, so one of the things Ive learned from all this is that cancer does not discriminate ... it will impact anyone.

I called my family physician the next day, and she scheduled a mammogram. I got the phone call on June 26 that it was breast cancer. On the same day, the Carlton Breast Center called and said I needed to come in immediately for an ultrasound and biopsy. I told them I was going away for a birthday weekend, and the person who called said, Did you hear what I just said? I told her, Yes, and did you hear what I just said? I had my weekend but scheduled an appointment for the ultrasound and biopsy the next Monday.

Wilsons cancer was detected early (Stage 1) but was found to be invasive, so she began a series of 33 radiation treatments. Shes in the midst of a 10-year regimen of hormone blockers, but she is now cancer-free.

Sure, there was some depression and anxiety during the treatment, but I never lost faith, Wilson said.

Success! An email has been sent to with a link to confirm list signup.

Error! There was an error processing your request.

Now, her experience allows her to give a first-hand accounting to young cancer patients as they face their own battle.

We have women as young as 27 and as old as 49, and my having been through this gives me an opportunity to give them some honest answers that often comforts them, she said of the Young Survivors Coalition.

In addition, both Fred and Monique Wilson participate in their Tour de Pink, an annual 200-mile bike ride they take part in in New Jersey to raise funds to support and increase awareness of breast cancer treatment and prevention.

We do the Tour de Pink to raise funds for other women and even men who will be diagnosed with breast cancer and for those who have passed on, Monique Wilson said.

This years virtual tree-lighting ceremony will be unveiled on Phoebes Facebook and YouTube channels Thursday at 7 p.m. And, since the annual Lights of Love event is a fundraiser for the Phoebe Foundation, that groups Mandy Tedder said the broadcast will include an opportunity for the community to donate to the foundation.

Tedder said she doesnt think the pandemic will stop supporters from giving.

I believe people are going to come across, she said. This is their opportunity to be part of something extra special. This is the 37th year for Lights of Love, and while people know they cant come out for the celebration, they can gather with their immediate family and still be a part of this community tradition.

Funds raised through Lights of Love have been used to purchase a van that has taken cancer patients to and from treatments and to purchase radiation equipment. Tedder said this years funds will top off efforts to re-open the Light House, which was destroyed by straight-line winds in January of 2017. The newly built Light House, which provides respite opportunities for families of cancer patients, will be opened early next year at the corner of Second Avenue and Monroe Street.

More here:
Monique Wilson tree-lighter for Phoebe's virtual Lights of Love - The Albany Herald

Recommendation and review posted by Bethany Smith

Amcenestrant (SAR439859), a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor (ER) positive, HER2-negative locally advanced or metastatic breast cancer.

The agent, a selective estrogen receptor degrader (SERD), is being compared with physicians choice of endocrine therapy in the open label, phase 2 trial AMEERA-3 trial (NCT04059484). The control treatment involves choosing monotherapy from a list of agents with different mechanisms of action: anastrozole, letrozole, or exemestane, which are aromatase inhibitors; tamoxifen, a selective estrogen receptor modulator; or fulvestrant (Faslodex), a SERD (Figure).1

Figure. SAR439859 in Locally Advanced or Metastatic Breast Cancer

Amcenestrant is a next-generation SERD that, in preclinical studies, has demonstrated antitumor efficacy and regression in ER-positive breast cancer models and can be administered as an oral therapy because of its favorable pharmacokinetic profile.2 Fulvestrant, which has been available since 2002, must be administered via intramuscular injection because of limitations including low solubility and weak permeation.3

Its exciting to have a potential SERD that is oral and has potentially better bioavailability than fulvestrant. So many of us wondered whether these [novel] agents could substitute for fulvestrant in the future and potentially be a better option, said Sara M. Tolaney, MD, MPH, principal investigator for the AMEERA-3 trial, in an interview with OncLive.

SERDs work by serving as competitive antagonists to the ER, inducing conformational changes that lead to degradation of the receptors. They have dual functions. I think this accounts for their ability to block the signaling in ER-dependent tumors that may be potentially resistant to other endocrine therapies, said Tolaney, who is associate director of the Susan F. Smith Center for Womens Cancers and director of Clinical Trials in Breast Oncology at Dana-Farber Cancer Institute in Boston, Massachusetts.

Amcenestrant has shown activity in patients regardless of ESR1 mutation status, which makes it very intriguing, added Tolaney, who also is an associate professor of medicine at Harvard Medical School in Boston. It is blocking the estradiol and binding to the estrogen receptor, which promotes inactivation and degradation. Its thought to do so more potently than fulvestrant does.

The goal of AMEERA-3 is to demonstrate that amcenestrant is superior to the endocrine therapy of physicians choice in patients who are refractory to endocrine therapy and have metastatic hormone receptor (HR)positive breast cancer, Tolaney said. The primary end point is progression-free survival (PFS). Secondary end points include overall survival (OS), objective response rate (ORR), disease control rate, clinical benefit rate (CBR), and duration of response (DOR).

Tolaney said the trial design takes into account the options available to patients with HR-driven breast cancer. In the first-line setting for metastatic hormonal receptorpositive disease, patients get a different endocrine backbone. Some patients are getting an aromatase inhibitor with CDK4/6 inhibition; some are getting fulvestrant with CDK4/6 inhibition. This trial allows for the flexibility for the physician to choose what is most appropriate for the patient based on their prior exposure to endocrine treatment, Tolaney said.

Amcenestrant is being administered at 400 mg daily in 28-day cycles until unacceptable toxicity, progression, death, investigator decision, or patient request.3 The comparators are being given based on approved labeling.4

In terms of eligibility requirements, the trial limits participants to 1 prior targeted therapy with a CDK4/6 inhibitor or 1 prior treatment with chemotherapy for advanced or metastatic disease. The criteria also require patients outside of China to receive a prior CDK4/6 inhibitor if they can get reimbursed for it; the number of participants without previous CDK4/6 inhibitor therapy will be capped at 20%. It has become standard of care to use CDK4/6 inhibitors with endocrine treatment in the first-line setting for metastatic, hormone receptorpositive disease, Tolaney noted.

Additionally, eligible patients are required to have progressed after 6 or more months of continuous endocrine therapy for advanced disease or to have relapsed while on adjuvant endocrine treatment for 2 or more years or within 12 months of receiving that therapy. Patients with brain metastases are excluded, as well those who previously received an mTOR inhibitor or a SERD other than fulvestrant, which must be stopped at least 3 months before randomization.

The trial seeks to enroll 282 patients through 126 worldwide locations. An extension is planned with an additional 90 Chinese participants expected to be enrolled. Tolaney said the trial is more than halfway accrued. It was a little delayed because of COVID [coronavirus disease 2019], but it has been doing well otherwise, she said. She anticipates enrollment will be completed early in 2021.

The rationale for AMEERA-3 stems from findings from an ongoing first-in human phase 1/2 study (NCT03284957) testing amcenestrant as monotherapy and in combination with other agents in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

Investigators presented results for patients who received amcenestrant monotherapy in 2 cohorts of the study at the 2020 American Society of Clinical Oncology Virtual Scientific Program. The pooled data included women who received from 150 mg to 600 mg daily in part A of the study and those who took 400 mg daily in part B of the study. The primary end point in part B was ORR, documented by RECIST v1.1 criteria; secondary end points included overall safety profile; ORR based on ESR1 status (mutated or wild type); and CBR defined as complete and partial responses plus stable disease for 24 weeks or more.5

All patients in the study (N = 62) had received prior endocrine therapy in the advanced setting; 48.4% had 3 or more previous lines of therapy. Among 59 evaluable patients, the ORR was 6.8% (90% CI, 2.3%-14.8%), all partial responses. The CBR was 35.6% (90% CI, 25.1%-47.1%), which study investigators said was similar to that of fulvestrant in less heavily pretreated patients. Patients with wild-type ESR1 (n = 30) had better responses than those with mutant ESR1 (n = 28) for ORR (10.0% vs 3.6%, respectively) and CBR (40.0% vs 32.1%).

In a subset of women without prior treatment with a SERD, CDK4/6 inhibitor, or mTOR inhibitor (n = 14), the antitumor activity of amcenestrant was substantially greater and compared favorably with historical results for fulvestrant. The ORR was 21.4% (90% CI, 6.1%-46.6%) and the CBR was 64.3% (90% CI, 39.0%-84.7%).

Amcenestrant had a favorable safety profile with limited treatment-related adverse effects (TRAEs); 61.3% of women in the study had adverse effects, and all were grade 1 or 2, most commonly hot flush (16.1%); constipation (9.7%); and arthralgia (9.7); decreased appetite, vomiting, diarrhea, nausea and decreased appetite (all 8.1%); and fatigue (6.5%). No patients discontinued because of TRAEs.

Amcenestrant has the potential to become the best-in-class endocrine backbone across treatment lines in HR-positive breast cancer, according to Paul Hudson, chief executive officer of Sanofi, the company developing the drug.6

Amcenestrant also is being evaluated in comparison with letrozole in an ongoing phase 2 window of opportunity study (NCT04191382) in newly diagnosed ER-positive, HER2-negative breast cancer.7 In this study, patients are being randomized to receive amcenestrant at 400 mg or 200 mg daily, or to receive letrozole at 2.5 mg daily for 14 days prior to surgery. Biopsies will be taken before and after therapy to assess tumor biomarkers.

The primary end point is a change in Ki-67 after a 14-treatment period compared with baselines levels via immunohistochemistry assessment in tumor tissue. Secondary end points include the proportion of patients with relative decrease from baseline in Ki-67 of 50% or more, change in ER expression compared with baseline, and safety and tolerability. Ki-67 is a biomarker of cellular proliferation, and expression of Ki-67 in 14% or more of tumor nuclei is associated with poor prognosis in early breast cancer, investigators noted. This study began enrolling patients in December 2019 and is being conducted at 16 sites worldwide.7

Another study, AMEERA-5 (NCT04478266)8, is testing amcenestrant in combination with palbociclib (Ibrance), a CDK4/6 inhibitor, versus letrozole plus palbociclib as a firstline therapy for patients with ER- positive, HER2-negative breast cancer. The study, which aims to recruit 810 patients, has a primary end point of PFS and secondary end points of OS, ORR, DOR, and CBR.

Additionally, the Quantum Leap Healthcare Collaborative announced in June 2020 that amcenestrant was selected to be part of a new I-SPY 2 study arm.7 The study, known as the I-SPY 2 Endocrine Optimization Protocol (EOP), is focused on patients with molecularly low-risk, clinically high-risk, HR-positive, HER2-negative clinical stage II or III invasive breast cancer. Amcenestrant will be tested as a monotherapy and in combination with up to 3 other agents.

The I-SPY program was designed to identify therapies that are most effective in specific patient subgroups based on biomarker signatures. Sanofi is supplying the drug and providing financial support.9

See the article here:
Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial - OncLive

Recommendation and review posted by Bethany Smith

A British pensioner says he wants to have his body frozen after death in the hope that future generations will one day be able to bring them back to life.

The unnamed 73-year-old, from Nottingham, has signed up to a programme that allows customers to be cryogenically frozen soon after death.

Their body will then be cooled and transported to the US where it will be placed in liquid nitrogen at a chilling temperature of -196C in a facility in Arizona, operated by the firm Alcor.

The scientific procedure is described as "life extension" and patients are put in "pause" before returning to humanity potentially thousands of years in the future when it is technologically and scientifically possible.

The man said: "The number of people signing up to cryonics isn't booming but it is increasing all the time, it has been for many years.

"Most people are taking up the option because there is less belief in religion these days and there's a gradual realisation that with the constant advances in science, cryonics will work.

"It is advancing at an exponential rate, it always has.

"Compare the time from the discovery of electricity or the invention to mobile phones to now, and then look to the end of this century.

"The advantage is extending your life for possibly a very long time. It's a way of taking advantage of technology that will be available in the future.

"Part of our role with Cryonics UK is to help you get there by cooling your body down as quickly as possible and doing our best to preserve it by using cryogenic preservatives to replace the blood and most of the water in your body so you won't suffer ice crystals in your brain, though in the future there will probably be a way of getting around that.

"Then we put your body in a large casket with dry ice that's minus 79 degrees and ship it off to America."

The British man's body will stored by Alcor, a firm specialising in 'life extension'. According to the company, the process is not new with people trying to prolong their lives since as far back as the 1960s.

Their services are not cheap, with the majority of patients usually needing a life insurance policy of $200,000 (150,000) for a "whole-body cryopreservation or $80,000 (60,000) for neuro cryopreservation".

It is vital the procedure begins within the first minute or two after the heart stops beating.

Alcor says: "Longer delays place a greater burden on future technology to reverse injury and restore the brain to a healthy state, and make it more uncertain that the correct original state can be determined.

"Except for embryos, no human has ever been revived from temperatures far below freezing."

See more here:
Brit pensioner plans to freeze his own corpse in hopes of being revived centuries later - Daily Star

Recommendation and review posted by Bethany Smith

The report offers a complete research study of the global Testosterone undecanoate Market that includes accurate forecasts and analysis at global, regional, and country levels. It provides a comprehensive view of the global Testosterone undecanoate Market and detailed value chain analysis to help players to closely understand important changes in business activities observed across the industry. It also offers a deep segmental analysis of the global Testosterone undecanoate market where key product and application segments are shed light upon. Readers are provided with actual market figures related to the size of the global Testosterone undecanoate market in terms of value and volume for the forecast period 2020-2027.

The following Companies as the Key Players in the Global Testosterone undecanoate Market Research Report are Bayer AG, Endo Pharmaceuticals, Merck Sharp & Dohme, Taro Pharmaceutical, Cipla, Zhejiang Xianju Pharmaceutical, Zhejiang Medicine Co..

Free Sample Report + All Related Graphs & Charts @ https://www.statsandreports.com/request-sample/352994-global-united-states-european-union-and-china-testosterone-undecanoate-market-research-report-2019-2025

Asia Pacific and Europe are projected to be Testosterone undecanoate markets during the forecast period. This is primarily due to the presence of prominent industry in China, Germany, Japan, and India.

Market Overview of Global Testosterone undecanoate

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Injection, Oral.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Primary hypogonadism, Hypogonadotropic hypogonadism, Late-onset hypogonadism.

Geographically, The Testosterone undecanoate market report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering: North America, Europe, China, Japan and others.

We are currently offering Quarter-end Discount to all our high potential clients and would really like you to avail the benefits and leverage your analysis based on our report.

Avail 30-50% Discount on various license type on immediate purchase (Use Corporate email ID to Get Higher Priority) @ https://www.statsandreports.com/check-discount/352994-global-united-states-european-union-and-china-testosterone-undecanoate-market-research-report-2019-2025

Furthermore, Global Testosterone undecanoate Market following points are involved along with a detailed study of each point:

Major Players: The report provides company profiling for a decent number of leading players of the global Testosterone undecanoate market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Testosterone undecanoate Market Dynamics: The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Global Testosterone undecanoate Market Forecast: Readers are provided with production and revenue forecasts for the global Testosterone undecanoate market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Testosterone undecanoate market by type, and consumption forecast for the global Testosterone undecanoate market by application.

Regional Market Analysis: It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Testosterone undecanoate Market Competition: In this section, the report provides information on Competitive situations and trends including merger and acquisition and expansion, market shares of the top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Get Customized Report in your Inbox within 24 hours at: https://www.statsandreports.com/enquiry-before/352994-global-united-states-european-union-and-china-testosterone-undecanoate-market-research-report-2019-2025

Major Highlights of Testosterone undecanoate Market in Covid-19 pandemic covered in report:

Market Competition by key manufacturers in the industry. Discussed Sourcing strategies, industrial chain information and downstream buyers data. Distributors and traders marketing strategy analysis focusing on region wise needs in covid-19 pandemic. Vendors who are providing a wide range of product lines and intensifying the competitive scenario in covid-19 crisis. Also highlights of the key growth sectors of Testosterone undecanoate market and how they will perform in coming years.

Buy Full Copy Global Testosterone undecanoate Report 2020-2027 @ https://www.statsandreports.com/placeorder?report=352994-global-united-states-european-union-and-china-testosterone-undecanoate-market-research-report-2019-2025&type=SingleUser

** The market is evaluated based on the weighted average selling price (WASP) and includes the taxes applicable to the manufacturer. All currency conversions used in the creation of this report were calculated using a certain annual average rate of 2020 currency conversion.

Crucial points encompassed in the report:

Customization Available

With the given market data, Researchers offer customization according to the companys specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Testosterone undecanoate market, by end-use.

Detailed analysis and profiles of additional market players.

About Us

Stats and Reports is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact:

Stats and ReportsMangalam Chamber, Office No 16, Paud RoadSankalp Society, Kothrud, Pune, Maharashtra 411038Phone: +1 650-646-3808Email: [emailprotected]Website: https://www.statsandreports.comFollow Us on: LinkedIN | Twitter |

Continued here:
Impact of Covid-19 on Testosterone undecanoate Market is slated to grow rapidly in the forthcoming years with Key Players Bayer AG, Endo...

Recommendation and review posted by Bethany Smith

New York, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User, and Country" - https://www.reportlinker.com/p05989496/?utm_source=GNW However, the low success rate of cell therapies and the high cost of cell-based research is expected to restrain the market growth during the forecast period.

Cell therapy typically involves the administration of somatic cell preparations by injecting or grafting it into the patients body for the treatment of diseases or traumatic damages.The procedure is used to cure diabetes, neurological disorders, related injuries, several cancer types, bones and joints, and genetic disorders.

Continuous research and development activities have led to unique cell therapeutic instruments for the improvement of immune system and efficient treatment of genetic disorders. Various market players provide several consumables such as reagent kits and enzymes as well as devices, equipment, and software to perform various cell therapy processes.

The use of instruments is essential for handling cell therapies such as NSC, PSC, MSC, T cells, and HSC.These cell therapy products are derived from animals or human cells and thus need to be protected from contamination.

The instruments used in cell therapies help provide protection against contamination and allow scaling up of transplantation. Companies such as Hitachi Chemical Advanced Therapeutics Solutions Corning Incorporated; Thermo Fisher Scientific Inc., MiltenyiBiotec, LLC; Invetech; and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy procedures.

The global COVID-19 emergency has been particularly affecting the supply chain worldwide.The supply chain disruptions, along with the enormous demand for effective therapies for the treatment of COVID-19, have put the healthcare research industry in a crucial situation in the Asia Pacific region.

However, many medical companies have realized the importance of cell therapy in the treatment of COVID 19, which would raise its demand in the coming years.

The Asia Pacific cell therapy instruments market, by product, is segmented into consumables, software, equipment, and systems.The consumables segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

On the basis of cell type, the cell therapy instruments market is segmented into animal cells and human cells. The human cells segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during the forecast period.

On the basis of process, the Asia Pacific cell therapy instruments market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control.The cell processing segment held the largest share of the market in 2019 and is estimated to register the highest CAGR during the forecast period.

The Asia Pacific cell therapy instruments market, based on end user, is segmented into life science research companies, research institutes, and other end users. The life science research companies segment accounted for the largest share of the market in 2019 and is anticipated to register the highest CAGR during the forecast period.

A few of the major primary and secondary sources associated with the Asia Pacific cell therapy instruments market are National Center for Biotechnology Information (NCBI); World Health Organization (WHO); Medical Research Future Fund (MRFF); Asia-Pacific Economic Corporation (APEC); and Global Institute of Stem Cell Therapy and Research (GIOSTAR).Read the full report: https://www.reportlinker.com/p05989496/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
Asia Pacific Cell Therapy Instruments Market Forecast to 2027 - Covid-19 Impact and Regional Analysis - By Product ; Cell Type ; Process ; End User,...

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms" report has been added to ResearchAndMarkets.com's offering.

The research provides technological insights across inflammation, infectious diseases, and microbiomics.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness from:

For more information about this report visit https://www.researchandmarkets.com/r/tkufmb

Read this article:
2020 Report: Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms - ResearchAndMarkets.com - Business Wire

Recommendation and review posted by Bethany Smith

A team of Irish scientists have developed a gene therapy that could potentially lead to a new treatment for an eye disease causing progressive loss of vision, which affects many thousands of people across the globe.

The breakthrough therapy, which offers hope for people with dominant optic atrophy (DOA), was devised by researchers at Trinity College Dublin in collaboration with clinicians at the Royal Victoria Eye and Ear Hospital and the Mater hospital in Dublin.

It also has implications for a much wider suite of neurological disorders associated with ageing which collectively affect millions of people worldwide.

DOA is an inherited disorder characterised by degeneration of optic nerves. It typically starts during the first decade of life. Affected people usually develop moderate visual loss and colour vision defects but severity varies, symptoms can worsen over time and some people become blind. At present, there is no way to prevent or cure DOA.

The scientists published their results in Frontiers in Neuroscience on Thursday.

A gene (OPA1) provides instructions for making a protein found in cells and tissues throughout the body that is pivotal to the proper function of mitochondria, the energy generators in cells.

Without the protein, mitochondrial function is sub-optimal; the normally well-interconnected mitochondrial network in healthy cells becomes highly disrupted. For those with DOA, it is mutations in OPA1 and the dysfunctional mitochondria that are responsible for onset and progression of the disorder.

Led by research fellow Dr Daniel Maloney and Prof Jane Farrar from TCD School of Genetics and Microbiology, the gene therapy successfully protected the visual function of mice who were treated with a chemical targeting the mitochondria and were consequently living with dysfunctional mitochondria.

The scientists also found the gene therapy improved mitochondrial performance in human cells that contained mutations in the OPA1 gene.

We used a clever lab technique that allows scientists to provide a specific gene to cells that need it using specially engineered non-harmful viruses, Dr Maloney said.

This allowed us to directly alter the functioning of the mitochondria in the cells we treated, boosting their ability to produce energy which, in turn, helps protect them from cell damage.

Excitingly, our results demonstrate that this OPA1-based gene therapy can potentially provide benefit for diseases like DOA, which are due to OPA1 mutations, and also possibly for a wider array of diseases involving mitochondrial dysfunction.

Mitochondrial dysfunction causes problems in neurological disorders such as Alzheimers and Parkinsons disease. The impacts gradually build up over time, which is why many may associate such disorders with ageing.

Prof Farrar added: We are very excited by the prospect of this new gene therapy strategy, although it is important to highlight that there is still a long journey to complete from a research and development perspective before this therapeutic approach may one day be available as a treatment.

Because mitochondrial dysfunction was implicated in so many neurological disorders, there was great potential for this type of therapeutic strategy to make a major societal impact, she said.

The research was supported by Science Foundation Ireland, the Health Research Board of Ireland, Fighting Blindness Ireland, and Health Research Charities Ireland.

Original post:
Irish scientists develop gene therapy for inherited vision loss disorder - The Irish Times

Recommendation and review posted by Bethany Smith

Nov. 24, 2020 12:00 UTC

Appoints former Chief Medical Officer of Spark Therapeutics, Kathy Reape, M.D., and Chief Scientific Officer of Intellia Therapeutics, Laura Sepp-Lorenzino, Ph.D., to board of directors

Directors bring significant gene therapy translational and development expertise ahead of GM2 gangliosidosis clinical trial initiation in 2020 and submission of four INDs by the end of 2021

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced the appointment of Kathy Reape, M.D., and Laura Sepp-Lorenzino, Ph.D., to the companys board of directors.

Drs. Reape and Sepp-Lorenzino bring significant gene therapy translational and development expertise to our board, said RA Session II, President, Founder and CEO of Taysha Gene Therapies. Their combined gene therapy experience across preclinical and clinical development will be invaluable as we continue to advance our broad portfolio into the clinic. Across all levels of the organization, we are building a team that has the passion, experience and talent to execute on our mission of eradicating monogenic CNS disease.

Dr. Reape was most recently Chief Medical Officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance and medical affairs activities and was a key member of the team responsible for the development and commercialization of the first FDA-approved in vivo gene therapy, LUXTURNA, for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. She also oversaw the development of Sparks pipeline of gene therapies addressing CNS disease, hemophilia, metabolic disorders and inherited retinal dystrophies. She has over 18 years of experience in the pharmaceutical industry in clinical research and development and has been involved with approximately two dozen product approvals including small molecules, biologics, biosimilars and therapeutic devices. She received both her undergraduate and M.D. degrees from the University of Pennsylvania and completed her internship and residency at the University of Florida and University of Medicine and Dentistry of New Jersey.

Taysha has built a deep pipeline of potentially transformative gene therapies for patients with life-threatening CNS diseases, said Dr. Reape. Many of the conditions that Taysha is addressing have no therapeutic alternatives, are associated with a poor quality of life and often result in a shortened life expectancy. It is important that we rapidly advance these gene therapies into the clinic to serve patients so desperately in need.

Dr. Sepp-Lorenzino is currently the Chief Scientific Officer at Intellia Therapeutics and has held several senior positions over her extensive career. Most recently, she was Vice President and Head of Nucleic Acid Therapies at Vertex Pharmaceuticals. She previously served as Alnylams Vice President and Entrepreneur-in-Residence, where she led the hepatic infectious disease strategies therapeutic area and was a key figure in partnering and in-licensing activities. She spent 14 years at Merck & Co., including as Executive Director and Department Head of the RNA therapeutics discovery biology unit. Dr. Sepp-Lorenzino received her degree in biochemistry at the University of Buenos Aires, Argentina and her M.S. and Ph.D. in biochemistry from New York University.

Joining the Taysha board is a truly exceptional opportunity to contribute to the development of multiple innovative gene therapies, commented Dr. Sepp-Lorenzino. Taysha is taking a leadership position in the industry by combining decades of gene therapy experience with a portfolio of programs that have the potential to address the underlying biology of various CNS disorders in order create an engine for potential new treatments.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platforman engine for potential new cureswith a goal of dramatically improving patients lives. More information is available at http://www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, intends, projects, and future or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the conduct or timing of our clinical trials and our research, development and regulatory plans for our product candidates, the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (SEC) filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which is available on the SECs website at http://www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005342/en/

See more here:
Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors - BioSpace

Recommendation and review posted by Bethany Smith

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020. Genprexs Executive Vice President and Chief Operating Officer, Michael Redman, will virtually deliver a company overview to investors followed by a guided question and answer session.

Event: Diamond Equity Research Emerging Growth InvitationalDate: Tuesday, December 1Time: 11:40 a.m. ESTRegistration Link: https://bit.ly/2UJS3Si

A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above. For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Read the rest here:
Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 - Business Wire

Recommendation and review posted by Bethany Smith

"Despite the projected growth in market applications andabundant investment capital, there is a danger that legal andethical concerns related to genetic research could put the brakeson gene editing technologies and product programs emanatingtherefrom."

There are thousands of diseases occurring in humans, animals,and plants caused by aberrant DNA sequences. Traditional smallmolecule and biologic therapies have only had minimal success intreating many of these diseases because they mitigate symptomswhile failing to address the underlying genetic causes. While humanunderstanding of genetic diseases has increased tremendously sincethe mapping of the human genome in the late 1990s, our ability totreat them effectively has been limited by our historical inabilityto alter genetic sequences.

The science of gene editing was born in the 1990s, as scientistsdeveloped tools such as zinc-finger nucleases (ZFNs) and TALEnucleases (TALENs) to study the genome and attempt to altersequences that caused disease. While these systems were anessential first step to demonstrate the potential of gene editing,their development was challenging in practice due to the complexityof engineering protein-DNA interactions.

Then, in 2011, Dr. Emmanuelle Charpentier, a French professor ofmicrobiology, genetics, and biochemistry, and Jennifer Doudna, anAmerican professor of biochemistry, pioneered a revolutionary newgene-editing technology called CRISPR/Cas9. Clustered Regularly InterspacedShort Palindromic Repeats (CRISPR) and Cas9 stands forCRISPR-associated protein 9. In 2020, the revolutionary work ofDrs. Charpentier and Doudna developing CRISPR/Cas9 were recognizedwith the Nobel Prize for Chemistry. The technology was also thesource of a long-running and high-profile patent battle between two groups ofscientsists.

CRISPR/Cas9 for gene editing came about from a naturallyoccurring viral defense mechanism in bacteria. The system ischeaper and easier to use than previous technologies. It deliversthe Cas9 nuclease complexed with a synthetic guide RNA (gRNA) intoa cell, cutting the 'cell's genome at the desired location,allowing existing genes to be removed and new ones added to aliving organism's genome. The technique is essential inbiotechnology and medicine as it provides for the genomes to beedited in vivo with extremely high precision, efficiently, and withcomparative ease. It can create new drugs, agricultural products,and genetically modified organisms or control pathogens and pests.More possibilities include the treatment of inherited geneticdiseases and diseases arising from somatic mutations such ascancer. However, its use in human germline genetic modification ishighly controversial.

The following diagram from CRISPR Therapeutics AG, a Swisscompany, illustrates how it functions:

In the 1990s, nanotechnology and gene editing were necessaryplot points for science fiction films. In 2020, developments likenano-sensors and CRISPR gene editing technology have moved thesetechnologies directly into the mainstream, opening a new frontierof novel market applications. According to The Business ResearchCompany, the global CRISPR technology market reached a value ofnearly $700 million in 2019, is expected to more than double in2020, and reach $6.7 billion by 2030. Market applications targetall forms of life, from animals to plants to humans.

Gene editing's primary market applications are for thetreatment of genetically-defined diseases. CRISPR/Cas9 gene editingpromises to enable the engineering of genomes of cell-basedtherapies and make them safer and available to a broader group ofpatients. Cell therapies have already begun to make a meaningfulimpact on specific diseases, and gene editing helps to acceleratethat progress across diverse disease areas, including oncology anddiabetes.

In the area of human therapy, millions of people worldwidesuffer from genetic conditions. Gene-editing technologies likeCRISPR-Cas9 have introduced a way to address the cause ofdebilitating illnesses like cystic fibrosis and create betterinterventions and therapies. They also have promising marketapplications for agriculture, food safety, supply, anddistribution. For example, grocery retailers are even looking athow gene editing could impact the products they sell. Scientistshave created gene-edited crops like non-browning mushrooms andmildew-resistant grapes - experiments that are part of an effort toprevent spoilage, which could ultimately change the way food issold.

Despite the inability to travel and conduct face-to-facemeetings, attend industry conferences or conduct business otherthan remotely or with social distance, the investment markets forventure, growth, and private equity capital, as well as corporateR&D budgets, have remained buoyant through 2020 to date.Indeed, the third quarter of 2020 was the second strongest quarterever for VC-backed companies, with 88 companies raising roundsworth $100 million or more according to the latest PwC/Moneytreereport. Healthcare startups raised over $8 billion in the quarterin the United States alone. Gene-editing company MammouthBiosciences raised a $45 million round of Series B capital in thesecond quarter of 2020. CRISPR Therapeutics AG raised more in thepublic markets in primary and secondary capital.

Bayer, Humboldt Fund and Leaps are co-leading a $65 million Series A round for Metagenomi, abiotech startup launched by UC Berkeley scientists. Metagenomi,which will be run by Berkeley's Brian Thomas, is developing atoolbox of CRISPR- and non-CRISPR-based gene-editing systems beyondthe Cas9 protein. The goal is to apply machine learning to searchthrough the genomes of these microorganisms, finding new nucleasesthat can be used in gene therapies. Other investors in the Series Ainclude Sozo Ventures, Agent Capital, InCube Ventures and HOFCapital. Given the focus on new therapies and vaccines to treat thenovel coronavirus, we expect continued wind in the sails forgene-editing companies, particularly those with strong productportfolios that leverage the technology.

Despite the projected growth in market applications and abundantinvestment capital, there is a danger that legal and ethicalconcerns related to genetic research could put the brakes ongene-editing technologies and product programs emanating therefrom.The possibility of off-target effects, lack of informed consent forgermline therapy, and other ethical concerns could cause governmentregulators to put a stop on important research and developmentrequired to cure disease and regenerate human health.

Gene-editing companies can only make money by developingproducts that involve editing the human genome. The clinical andcommercial success of these product candidates depends on publicacceptance of gene-editing therapies for the treatment of humandiseases. Public attitudes could be influenced by claims that geneediting is unsafe, unethical, or immoral. Consequently, productscreated through gene editing may not gain the acceptance of thegovernment, the public, or the medical community. Adverse publicreaction to gene therapy, in general, could result in greatergovernment regulation and stricter labeling requirements ofgene-editing products. Stakeholders in government, third-partypayors, the medical community, and private industry must work tocreate standards that are both safe and comply with prevailingethical norms.

The most significant danger to growth in gene-editingtechnologies lies in ethical concerns about their application tohuman embryos or the human germline. In 2016, a group of scientistsedited the genome of human embryos to modify the gene forhemoglobin beta, the gene in which a mutation occurs in patientswith the inherited blood disorder beta thalassemia. Althoughconducted in non-viable embryos, it shocked the public thatscientists could be experimenting with human eggs, sperm, andembryos to alter human life at creation. Then, in 2018, abiophysics researcher in China created the first human geneticallyedited babies, twin girls, causing public outcry (and triggeringgovernment sanctioning of the researcher). In response, the WorldHealth Organization established a committee to advise on thecreation of standards for gene editing oversight and governancestandards on a global basis.

Some influential non-governmental agencies have called for amoratorium on gene editing, particularly as applied to altering thecreation or editing of human life. Other have set forth guidelineson how to use gene-editing technologies in therapeuticapplications. In the United States, the National Institute ofHealth has stated that it will not fund gene-editing studies inhuman embryos. A U.S. statute called "The Dickey-WickerAmendment" prohibits the use of federal funds for researchprojects that would create or destroy human life. Laws in theUnited Kingdom prohibit genetically modified embryos from beingimplanted into women. Still, embryos can be altered in researchlabs under license from the Human Fertilisation and EmbryologyAuthority.

Regulations must keep pace with the change that CRISPR-Cas9 hasbrought to research labs worldwide. Developing international guidelines could be a steptowards establishing cohesive national frameworks. The U.S.National Academy of Sciences recommended seven principles for thegovernance of human genome editing, including promoting well-being,transparency, due care, responsible science, respect for persons,fairness, and transnational co-operation. In the United Kingdom, anon-governmental organization formed in 1991 called The NuffieldCouncil has proposed two principles for the ethical acceptabilityof genome editing in the context of reproduction. First, theintervention intends to secure the welfare of the individual borndue to such technology. Second, social justice and solidarityprinciples are upheld, and the intervention should not result in anintensifying of social divides or marginalizing of disadvantagedgroups in society. In 2016, in application of the same, the CrickInstitute in London was approved to use CRISPR-Cas9 in humanembryos to study early development. In response to a cacophony ofconflicting national frameworks, the International Summit on HumanGene Editing was formed in 2015 by NGOs in the United States, theUnited Kingdom and China, and is working to harmonize regulationsglobal from both the ethical and safety perspectives. As CRISPRco-inventor Jennifer Doudna has written in a now infamous editorialin SCIENCE, "stakeholders must engage in thoughtfullycrafting regulations of the technology without stiflingit."

The COVID-19 pandemic has forced us to rely more on newtechnologies to keep us healthy, adapt to working from home, andmore. The pandemic makes us more reliant on innovative digital,biological, and physical solutions. It has created a united senseof urgency among the public and private industry (together withgovernment and academia) to be more creative about using technologyto regenerate health. With continued advances in computing power, networkarchitecture, communications bandwidths, artificial intelligence,machine learning, and gene editing, society will undoubtedly findmore cures for debilitating disease and succeed in regeneratinghuman health. As science advances, it inevitably intersects withlegal and ethical norms, both for individuals and civil society,and there are new externalities to consider. Legal and ethicalnorms will adapt, rebalancing the interests of each. The fourthindustrial revolution is accelerating, and hopefully towards curingdisease.

Originally published by IPWatchdog.com, November 24,2020.

The content of this article is intended to provide a generalguide to the subject matter. Specialist advice should be soughtabout your specific circumstances.

Here is the original post:
Future Visioning The Role Of CRISPR Gene Editing: Navigating Law And Ethics To Regenerate Health And Cure Disease - Technology - United States -...

Recommendation and review posted by Bethany Smith

Market Study Report, LLC, has recently added a report on the Gene Therapy market which presents substantial inputs about the market size, market share, regional trends, and profit projection of this business sphere. The report also enlightens users regarding the foremost challenges and existing growth tactics implemented by the leading organizations that constitute the dynamic competitive gamut of this industry.

The Gene Therapy market is projected to accomplish a very enviable valuation portfolio by the end of the estimated duration, claims this report. The research study also enumerates that this vertical will register a highly commendable growth rate over the forecast timeframe, while simultaneously elucidating a pivotal overview of this business space. Inclusive of highly significant details pertaining to the overall valuation presently held by this industry, the report also lists down, in meticulous detail, the segmentation of the Gene Therapy market and the growth opportunities prevailing across this vertical.

Request a sample Report of Gene Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2476988?utm_source=cheshire.media&utm_medium=Ram

Enumerating a basic coverage of the Gene Therapy market report:

What pointers are covered in the report with respect to the geographical spectrum of Gene Therapy market?

How meticulously is the Gene Therapy market segmented?

. The report comprises details about the market share that each product holds and the projected valuation of the segment.

. The market share which each application holds alongside the projected valuation that each application will account for is also incorporated in the study.

Ask for Discount on Gene Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2476988?utm_source=cheshire.media&utm_medium=Ram

What are the drivers & challenges of the Gene Therapy market?

An analysis of the important competitors in the Gene Therapy market:

The Gene Therapy market report is also comprised of some details such as market concentration ratio, spanning the concentration classes CR3, CR10, and CR5 over the projected timeline.

Enquiry about Gene Therapy market report before Buying at:https://www.marketstudyreport.com/enquiry-before-buying/2476988?utm_source=cheshire.media&utm_medium=Ram

Related Reports:

1. Global Animal Used Parasiticides Market Growth (Status and Outlook) 2020-2025Read More: https://www.marketstudyreport.com/reports/global-animal-used-parasiticides-market-growth-status-and-outlook-2020-2025

2. Global Advanced Wound Care Biologics Market Growth 2020-2025Read More: https://www.marketstudyreport.com/reports/global-advanced-wound-care-biologics-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/direct-to-consumer-genetic-testing-market-analysis-growth-by-top-companies-trends-by-types-and-application-forecast-to-2025-2020-11-26

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the rest here:
Global Gene Therapy Market Size, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2025 - Cheshire Media

Recommendation and review posted by Bethany Smith

The Global Gene Therapy Market Research Report Forecast 2020 2024 provides a comprehensive analysis of the market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of the global industry. It provides an in-depth study of the Gene Therapy market by using SWOT analysis. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

The global gene therapy market is expected to reach US$6.42 billion in 2024, witnessing growth at a CAGR of 19.29%, over the period 2020-2024.

(Exclusive Offer: Up to 10% discount on this report)

Get a Sample PDF Copy of the Latest Research on Gene Therapy Market 2020 Before the purchase:

https://www.marketinsightsreports.com/reports/08312273097/global-gene-therapy-market-by-cell-type-vector-type-application-end-user-region-insights-forecast-with-potential-impact-of-covid-19-2020-2024/inquiry?mode=69

Segmentation:

Top Key Players in the Global Gene Therapy Market: Roche Holding AG, Pfizer Inc., Novartis International AG, GlaxoSmithKline PLC, Bristol Myers Squibb Co. (Celgene Corporation) and Gilead Sciences, Inc.

Growth in the gene therapy market has accrued due to the increasing prevalence of chronic diseases, rising healthcare expenditure, expanding urbanization, growth of gene therapy clinical trials and upsurge in economic growth. The market is anticipated to experience certain trends like rapid adoption of personalized medicine, growing occurrence of genetic disorders, advancements in gene therapy and increasing R&D funding. The growth of the market would be challenged by side effects of gene therapy and ethical and safety concerns and high cost of the treatment.

The global gene therapy market has been segmented on the basis of cell type, vector type, application, end-user and region. Depending on the cell type, the market can be bifurcated into somatic cell gene therapy and germ cell gene therapy. According to the vector type, the global gene therapy market can be categorized into retrovirus & gammaretrovirus, adeno-associated viruses (AAV), lentivirus, adenovirus, modified herpes simplex virus and non-viral plasmid vector. Whereas, on the basis of application, the market can be split into oncological disorders, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases and others. Further, in terms of end-user, the global gene therapy market can broadly be segmented into hospitals, specialty treatment centers and other end-users.

The fastest growing regional market is North America due to the rising incidence of cancer and other target diseases, increasing favorable reimbursement scenario in the region and improvements in healthcare infrastructure. Further, the sudden outbreak of COVID-19 is causing an adverse disruption on the overall economy and society, affecting the rate of gene therapy procedures and clinical trials, which is expected to negatively impact the growth of the global gene therapy market during the forecasted period.

Scope of the report:

The report provides a comprehensive analysis of the global gene therapy market segmented on the basis of cell type, vector type, application, end-user and region. The major regional and country markets (North America, Europe, Asia Pacific and Rest of the World) have been analyzed. The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth. The competitive landscape of the market, along with the company profiles of leading players (Roche Holding AG, Pfizer Inc., Novartis International AG, GlaxoSmithKline PLC, Bristol Myers Squibb Co. (Celgene Corporation) and Gilead Sciences, Inc.) are also presented in detail.

Regional Analysis for Market:

For a comprehensive understanding of market dynamics, the global Gene Therapy market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India, and others. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

This Gene Therapy Market statistical surveying report underlines the leading merchants in this market everywhere throughout the world. This sector of the report includes market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue. In a comparable way, automated gathering, upstream raw materials, and downstream demand studies are administered.

Browse Complete Report details with Table of Content:

https://www.marketinsightsreports.com/reports/08312273097/global-gene-therapy-market-by-cell-type-vector-type-application-end-user-region-insights-forecast-with-potential-impact-of-covid-19-2020-2024?mode=69

Table Of Content:

Overview: This segment offers an overview of the report to provide an idea regarding the contents and nature of the research report along with a wide synopsis of the global Gene Therapy Market.

Analysis of Leading Players Strategies: Market top players can utilize this analysis to increase the upper hand over their rivals in the market.

Study on Major Market Trends: This segment of the report delivers a broad analysis of the most recent and future market trends.

Forecasts of the Market: The report gives production, consumption, sales, and other market forecasts. Report Buyers will approach exact and approved evaluations of the total market size in terms of value and volume.

Analysis of Regional Growth: This report covered all major regions and countries. The regional analysis will assist market players to formulate strategies specific to target regions, tap into unexplained regional markets, and compare the growth of all regional markets.

The research includes historic data from 2015 to 2020 and forecasts until 2024 which makes the reports an invaluable resource for industry executives, marketing, sales, and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Buy Full Report:

https://www.marketinsightsreports.com/report/purchase/08312273097?mode=su?mode=69

Customization of this Report:This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please contact our sales professional ([emailprotected]), we will ensure you obtain the report which works for your needs.

Note: All the reports that we list have been tracking the impact of COVID-19 on the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:

Market Insights Reports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. Market Insights Reports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

Email:[emailprotected] |[emailprotected]

More:
Gene Therapy Market Insights and Global Research and Clinical Survey Report 2020-2024 - The Market Feed

Recommendation and review posted by Bethany Smith

The latest report published by Polaris Market Research, titled Global Gene Therapy Market provides key information about the current status and prospects of the market. The report focuses on the market size, share, growth, emerging trends, and regional analysis of the market. The study also includes a comprehensive analysis of the various market factors, including market drivers, restraints, trends, risk, and opportunities prevailing within the market.

The report provides an in-depth analysis of the global Gene Therapy market that could help market players to devise their strategies and leads to the profitability of their business. The study also profiles key companies present in the market along with their market shares, growth rate, and product launches. The rapidly changing market scenario covering the initial and future assessment of the impact is covered in the report. Further, the report provides niche insights for every possible segment to help market players in the strategic decision-making process and market size estimation of the global Gene Therapy market on a regional and global basis.

Get a Sample Copy of the Report: https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/request-for-sample

The report produced by Polaris Market Research is widely known for its accuracy as it consists of precise graphs, tables, and figures that give a clear picture of the developments of the products and their market performance in the past and predicts the future trend. It uses statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analysis.

Manufacturers covered in this report are:

Novartis Pharmaceuticals Corporation, Kite Pharma, Incorporated, Spark Therapeutics, Inc, GlaxoSmithKline, Adaptimmune, Bluebird bio

*Note: Additional companies can be included on request

Geographical Overview

The report provides an extensive analysis of the key geographical regions of the market. The regional analysis focused on North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa regions. The report offers insightful information such as demand and supply, production and consumption ratio, import and export, and demand trends in each region. The report also includes covers a country-specific analysis of the each segment and sub-segment of the Gene Therapy market.

Impact of COVID-19

The report also takes into account the impact of the ongoing global crisis of the COVID-19 pandemic, on the global Gene Therapy market. It covers the key information current status of the industries and predicts the post-COVID-19 impact on the global market. The report also sheds light on the financial impact on businesses at the domestic level as well as global level. Polaris Market Research has gathered insights from various industry delegates and has been involved in primary and secondary research to provide customers with data and strategies to address market challenges during COVID-19 and post the COVID-19 pandemic.

Key questions answered in the report

The global Gene Therapy market report will help clients to gain an in-depth understanding of the global Gene Therapy market. The report identifies the ongoing market trend and anticipated growth in the near future to help industry vendors, manufacturers, consultants, and suppliers to align their market-centric strategies. The analytical studies are conducted to identify ensure customer requirements with a thorough understanding of the market capacities.

If you have any special requirements, please let us know and we will offer you the report as you want. Speak to Analyst to know more @ https://www.polarismarketresearch.com/industry-analysis/gene-therapy-market/speak-to-analyst

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us

Corporate Sales, USA

Polaris Market Research

Phone: 1-646-568-9980

Email: [emailprotected]

Web: http://www.polarismarketresearch.com

See the rest here:
Gene Therapy Market Potential Growth, Share and Demand-Analysis of Key Players- Research Forecasts - Cheshire Media

Recommendation and review posted by Bethany Smith

Bridging the gap: SYNGAP1 protein is located mostly at synapses, the junctions between neurons (green). Editors Note

This article was originally published on 24 November, based on preliminary data presented at a conference. We have updated the article to provide additional context.

Spectrum is covering the 2020 International SYNGAP1 Scientific Conference, which took place virtually because of the coronavirus pandemic. Here were highlighting researchers reactions to noteworthy presentations.

Drug test: A new assay allows researchers to test thousands of candidate drugs for their ability to boost expression of the autism gene SYNGAP1. The tool may help researchers identify and screen potential treatments for people with mutations that silence the gene. Gavin Rumbaugh, professor of neuroscience at Scripps Research in Jupiter, Florida, presented the unpublished results on 18 November.

The assay uses neurons from mice with one intact and one mutated copy of SYNGAP1. The researchers genetically engineer the mice so that SYNGAP1 protein made from the intact copy is tagged with luciferase the enzyme that gives fireflies their glow.

They then grow these neurons in tiny wells and add a different candidate drug to each well. The amount of SYNGAP1 protein in the dish gives a proportionate amount of light in your well, Rumbaugh says.

Rumbaugh and his team plan to use the platform to run through more than 100,000 different experimental compounds in 2021, he says.

Thats going to be really exciting for drug discovery efforts for SYNGAP1. I think thats going to be a game changer, says Karun Singh, senior scientist at the University Health Network in Toronto, Canada, who was not involved in the work.

It will be very exciting to see if they are able to uncover any useful hits with their novel approach, says Helen Bateup, associate professor of neurobiology at the University of California, Berkeley, who was not involved in the work.

Treatment across ages: A leading theory of autism is that the condition is characterized by a signaling imbalance: too much excitation or too little inhibition in the brain. One of the key players in creating this imbalance is thought to be inhibitory interneurons, which employ the neurotransmitter gamma-aminobutyric acid (GABA). And mutations to SYNGAP1 may disrupt GABAs function, said James Clement, assistant professor of neuroscience at the Jawaharlal Nehru Centre for Advanced Scientific Research in Bangalore, India, in a presentation on 18 November.

GABA is excitatory early on in brain development and inhibitory later on a switch that seems to be impaired in mice with SYNGAP1 mutations, he says. He and his team have tested a new compound that restores the GABA switch in mice and eases almost all SYNGAP1-related traits including seizures, learning issues and motor impairment in the mice. It works in newborn and adolescent mice. Due to a pending patent application, Clement and his lab are not revealing the compounds name.

I think its important to test efficacy at multiple ages, as they have done, to understand which phenotypes or problems can be improved with early treatment and which might still be responsive to treatment even if its administered later in life, says Bateup, who was not involved in the work. The idea that GABA may remain depolarizing for longer in SYNGAP1 mutant mice is quite interesting.

Clements lab was the only other lab that was presenting at this meeting that presented data from a very early age, says Shilpa Kadam, associate professor of neurology at the Kennedy Krieger Institute in Baltimore, Maryland, who was not involved in the work. Kadam also presented results on mice with SYNGAP1 mutations, showing that from an early age, theseanimalshave seizures thatcan be treated by blocking one type of GABA receptor.

Motor coordination: For mice, the loss of SYNGAP1 function in the striatum impairs their goal-directed learning and seems to lead to inflexible behavior, Bateup said in a presentation on 18 November.

Helen Bateups work looking at striatal function as it relates to motor coordination and motor learning is also pretty exciting and may shed light not only on the motor-coordination difficulties but also the repetitive or habitual motor behaviors, says Constance Smith-Hicks, child neurologist and research scientist at the Kennedy Krieger Institute, who was not involved in the work.

Bateups presentation also demonstrated that SYNGAP1 deletion seems to affect neurons differently depending on which type of dopamine receptor they express.

We know SYNGAP1 is at most excitatory synapses, so why shes seeing some functional effects in one type of cell and not the other, I find that interesting, says Richard Huganir, professor of neuroscience and psychological and brain sciences at Johns Hopkins University in Baltimore, Maryland, who was not involved in the work.

Its exciting to be able to kind of pinpoint which pathway might be involved and get a better understanding of the circuits that are disrupted, says Singh, who was not involved in the work.

Protein levels: People with a nonfunctional copy of SYNGAP1 have about half the typical amount of SYNGAP1 protein. Increasing the activity of the intact copy of the gene could help restore typical functioning, Huganir said in a presentation on 18 November.

He and his team tested this idea on two unique mouse models in unpublished work. Instead ofhaving one intact and one missing copyof the SYNGAP1 gene, as is typical for SYNGAP1 mouse models, each mouse model carriesone intact copy of the gene and one with a mutation seen in people. Both mice produce about half the typical amount of SYNGAP1 protein and show the same behaviors as the classical knockout mouse, despite having different types of mutations.

These new mouse models are crucial because they can directly correlate to what is happening in the humans, says Clement, who was not involved in the work.

Huganir and his team are testing different types of gene therapies to increase SYNGAP1 protein up to the typical levels, and have found that there are two SYNGAP1 protein isoforms, or slight variations of the protein.

One of the isoforms can restore synaptic plasticity in the animal model for SYNGAP1, so I think thats really exciting because even though theres multiple isoforms, it seems that one might be more important from a gene therapy point of view, says Singh, who was not involved in the work. Its pretty exciting to have a specific target now.

Read more reports from the2020 International SYNGAP1 Scientific Conference.

Continue reading here:
Reactions from the 2020 SYNGAP1 Scientific Conference - Spectrum

Recommendation and review posted by Bethany Smith

New York, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ; End User, and Country" - https://www.reportlinker.com/p05989572/?utm_source=GNW

The surge in the number of cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell and gene therapy products drive the growth of the North America cell therapy instruments market. However, the low success rate of cell therapies and the high cost of cell-based research is expected to restrain the market growth during the forecast period.

Cell therapy typically involves the administration of somatic cell preparations by injecting or grafting it into the patients body for the treatment of diseases or traumatic damages.The procedure is used to cure diabetes, neurological disorders, related injuries, several cancer types, bones and joints, and genetic disorders.

Continuous research and development activities have led to unique cell therapeutic instruments for the improvement of immune system and efficient treatment of genetic disorders. Various market players provide several consumables such as reagent kits and enzymes as well as devices, equipment, and software to perform various cell therapy processes.

The cell therapy products are derived from animals or human cells and thus need to be protected from contamination.The instruments used in cell therapies help provide protection against contamination and allow scaling up of transplantation.

Companies such as Hitachi Chemical Advanced Therapeutics Solutions; Corning Incorporated; Thermo Fisher Scientific Inc.; Miltenyi Biotec, LLC; Invetech, and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy procedures.

In North America, various healthcare research centers are focused specifically on COVID 19 therapeutics.During the initial phase of COVID-19 crisis, the demand for cell therapy instruments was disrupted owing to change in customer behaviors due to lockdown and supply chain disruptions.

However, the lack of definitive therapy offers significant opportunities for cell therapy instrumentation market players as US FDA has recently approved use of plasma therapy for critically ill COVID 19 patients. Further, the cell therapy instruments market also has significant growth prospects during the post-pandemic period.

On the basis of product, the North America cell therapy instruments market is further segmented into consumables, software, equipment, and systems.The consumables segment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

The cell therapy instruments market, based on cell type, is segmented into animal cells and human cells. The human cells segment held a larger share of the market in 2019 and is estimated to register a higher CAGR during 20202027.

On the basis of process, the North America cell therapy instruments market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control.The cell processing segment held the largest share of the market in 2019 and is estimated to register the highest CAGR during the forecast period.

The North America cell therapy instruments market, based on end user, is segmented into life science research companies, research institutes, and other end users. The life science research companies segment grasped the greatest share of the market in 2019 and is anticipated to register the highest CAGR from 2020 to 2027.

A few of the major primary and secondary sources associated with this report on the North America cell therapy instruments market are National Center for Biotechnology Information (NCBI); World Health Organization (WHO); American Society of Gene & Cell Therapy (ASGCT); and Global Institute of Stem Cell Therapy and Research (GIOSTAR).Read the full report: https://www.reportlinker.com/p05989572/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
North America Cell Therapy Instruments Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; Cell Type ; Process ; End User,...

Recommendation and review posted by Bethany Smith

The report provides revenue of the global Gene Therapy in Oncology market for the period 20162026, considering 2019 as the base year and 2026 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global market during the forecast period. The global Gene Therapy in Oncology market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2026.

With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.

Due to the high success rate during the preclinical and clinical trial, cancer gene therapy is gaining popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the Gene Therapy in Oncology market across the globe.

Request Coronavirus Impact Analysis on This [emailprotected] https://www.qyresearchmedical.com/sample/57077

A comprehensive estimate on the Gene Therapy in Oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of Gene Therapy in Oncology during the forecast period. Price point comparison by region with global average price is also considered in the study.

It is pertinent to consider that in a volatile global economy, we havent just conducted Gene Therapy in Oncology market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

Download Full Report https://www.qyresearchmedical.com/report/checkout/57077/3500

Drivers and Restraints

This section covers the various factors driving the global Advanced Driver Assistance Systems (ADAS) market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market.

Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market.

Market Segmentation:

The report is divided into major categories comprising product, application, regions and others. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Every segment is studied thoroughly in order to offer a better picture to the buyers and stakeholders to benefit from. Information like highest prevailing product, highly demanded product by the application segment and end users are rightly mentioned in the Gene Therapy in Oncology report.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global Gene Therapy in Oncology market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global Gene Therapy in Oncology market.

Gene Therapy in Oncology Breakdown Data by TypeEx VivoIn VivoGene Therapy in Oncology Breakdown Data by ApplicationHospitalsDiagnostics CentersResearch Institutes

In this study, the years considered to estimate the market size of Gene Therapy in Oncology are as follows:

Major Players Covered in this Report

The updated market research report on Gene Therapy in Oncology market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

Bristol-Myers SquibbCold GenesysAdvantageneAmgenAstraZenecaBio-Path HoldingsCRISPR TherapeuticsEditas MedicineGeron CorpIdera PharmaceuticalsIntellia TherapeuticsJohnson & JohnsonMarsala BiotechMerckMologen AGOncolytics BiotechOncosecOncotelicShenzhen SiBiono GeneTechSillajen BiotherapeuticsTocagenUniQureZiopharm Oncology

Regional Insights:

The Gene Therapy in Oncology market is segmented as North America, South America, Europe, Asia Pacific, and Middle East and Africa. Researchers have thoroughly studied about the historical market. With extensive research, experts have offered details on the current and the forecast demand made by these regions. The Gene Therapy in Oncology report also includes highlights on the prevailing product demanded by end users and end customers for better understanding of product demand by producers. This will help the producers and the marketing executives to plan their production quantity and plan effective marketing strategies to more buyers. Businesses can hence, increase their product portfolio and expand their global presence. Gene Therapy in Oncology market research report further offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. This will again help the manufacturers to increase their customers and emerge as leaders in the near future.

TABLE OF CONTENT

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Gene Therapy in Oncology Revenue1.4 Market Analysis by Type1.4.1 Global Gene Therapy in Oncology Market Size Growth Rate by Type: 2020 VS 20261.4.2 Ex Vivo1.4.3 In Vivo1.5 Market by Application1.5.1 Global Gene Therapy in Oncology Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Diagnostics Centers1.5.4 Research Institutes1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy in Oncology Industry Impact1.6.1 How the Covid-19 is Affecting the Gene Therapy in Oncology Industry1.6.1.1 Gene Therapy in Oncology Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Gene Therapy in Oncology Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Gene Therapy in Oncology Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered

2 Global Growth Trends by Regions2.1 Gene Therapy in Oncology Market Perspective (2015-2026)2.2 Gene Therapy in Oncology Growth Trends by Regions2.2.1 Gene Therapy in Oncology Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Gene Therapy in Oncology Historic Market Share by Regions (2015-2020)2.2.3 Gene Therapy in Oncology Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Gene Therapy in Oncology Market Growth Strategy2.3.6 Primary Interviews with Key Gene Therapy in Oncology Players (Opinion Leaders)

3 Competition Landscape by Key Players3.1 Global Top Gene Therapy in Oncology Players by Market Size3.1.1 Global Top Gene Therapy in Oncology Players by Revenue (2015-2020)3.1.2 Global Gene Therapy in Oncology Revenue Market Share by Players (2015-2020)3.1.3 Global Gene Therapy in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Gene Therapy in Oncology Market Concentration Ratio3.2.1 Global Gene Therapy in Oncology Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy in Oncology Revenue in 20193.3 Gene Therapy in Oncology Key Players Head office and Area Served3.4 Key Players Gene Therapy in Oncology Product Solution and Service3.5 Date of Enter into Gene Therapy in Oncology Market3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)4.1 Global Gene Therapy in Oncology Historic Market Size by Type (2015-2020)4.2 Global Gene Therapy in Oncology Forecasted Market Size by Type (2021-2026)

5 Gene Therapy in Oncology Breakdown Data by Application (2015-2026)5.1 Global Gene Therapy in Oncology Market Size by Application (2015-2020)5.2 Global Gene Therapy in Oncology Forecasted Market Size by Application (2021-2026)

6 North America6.1 North America Gene Therapy in Oncology Market Size (2015-2020)6.2 Gene Therapy in Oncology Key Players in North America (2019-2020)6.3 North America Gene Therapy in Oncology Market Size by Type (2015-2020)6.4 North America Gene Therapy in Oncology Market Size by Application (2015-2020)

7 Europe7.1 Europe Gene Therapy in Oncology Market Size (2015-2020)7.2 Gene Therapy in Oncology Key Players in Europe (2019-2020)7.3 Europe Gene Therapy in Oncology Market Size by Type (2015-2020)7.4 Europe Gene Therapy in Oncology Market Size by Application (2015-2020)

8 China8.1 China Gene Therapy in Oncology Market Size (2015-2020)8.2 Gene Therapy in Oncology Key Players in China (2019-2020)8.3 China Gene Therapy in Oncology Market Size by Type (2015-2020)8.4 China Gene Therapy in Oncology Market Size by Application (2015-2020)

9 Japan9.1 Japan Gene Therapy in Oncology Market Size (2015-2020)9.2 Gene Therapy in Oncology Key Players in Japan (2019-2020)9.3 Japan Gene Therapy in Oncology Market Size by Type (2015-2020)9.4 Japan Gene Therapy in Oncology Market Size by Application (2015-2020)

10 Southeast Asia10.1 Southeast Asia Gene Therapy in Oncology Market Size (2015-2020)10.2 Gene Therapy in Oncology Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Gene Therapy in Oncology Market Size by Type (2015-2020)10.4 Southeast Asia Gene Therapy in Oncology Market Size by Application (2015-2020)

11 India11.1 India Gene Therapy in Oncology Market Size (2015-2020)11.2 Gene Therapy in Oncology Key Players in India (2019-2020)11.3 India Gene Therapy in Oncology Market Size by Type (2015-2020)11.4 India Gene Therapy in Oncology Market Size by Application (2015-2020)

12 Central & South America12.1 Central & South America Gene Therapy in Oncology Market Size (2015-2020)12.2 Gene Therapy in Oncology Key Players in Central & South America (2019-2020)12.3 Central & South America Gene Therapy in Oncology Market Size by Type (2015-2020)12.4 Central & South America Gene Therapy in Oncology Market Size by Application (2015-2020)

13 Key Players Profiles13.1 Bristol-Myers Squibb13.1.1 Bristol-Myers Squibb Company Details13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue13.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Introduction13.1.4 Bristol-Myers Squibb Revenue in Gene Therapy in Oncology Business (2015-2020))13.1.5 Bristol-Myers Squibb Recent Development13.2 Cold Genesys13.2.1 Cold Genesys Company Details13.2.2 Cold Genesys Business Overview and Its Total Revenue13.2.3 Cold Genesys Gene Therapy in Oncology Introduction13.2.4 Cold Genesys Revenue in Gene Therapy in Oncology Business (2015-2020)13.2.5 Cold Genesys Recent Development13.3 Advantagene13.3.1 Advantagene Company Details13.3.2 Advantagene Business Overview and Its Total Revenue13.3.3 Advantagene Gene Therapy in Oncology Introduction13.3.4 Advantagene Revenue in Gene Therapy in Oncology Business (2015-2020)13.3.5 Advantagene Recent Development13.4 Amgen13.4.1 Amgen Company Details13.4.2 Amgen Business Overview and Its Total Revenue13.4.3 Amgen Gene Therapy in Oncology Introduction13.4.4 Amgen Revenue in Gene Therapy in Oncology Business (2015-2020)13.4.5 Amgen Recent Development13.5 AstraZeneca13.5.1 AstraZeneca Company Details13.5.2 AstraZeneca Business Overview and Its Total Revenue13.5.3 AstraZeneca Gene Therapy in Oncology Introduction13.5.4 AstraZeneca Revenue in Gene Therapy in Oncology Business (2015-2020)13.5.5 AstraZeneca Recent Development13.6 Bio-Path Holdings13.6.1 Bio-Path Holdings Company Details13.6.2 Bio-Path Holdings Business Overview and Its Total Revenue13.6.3 Bio-Path Holdings Gene Therapy in Oncology Introduction13.6.4 Bio-Path Holdings Revenue in Gene Therapy in Oncology Business (2015-2020)13.6.5 Bio-Path Holdings Recent Development13.7 CRISPR Therapeutics13.7.1 CRISPR Therapeutics Company Details13.7.2 CRISPR Therapeutics Business Overview and Its Total Revenue13.7.3 CRISPR Therapeutics Gene Therapy in Oncology Introduction13.7.4 CRISPR Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)13.7.5 CRISPR Therapeutics Recent Development13.8 Editas Medicine13.8.1 Editas Medicine Company Details13.8.2 Editas Medicine Business Overview and Its Total Revenue13.8.3 Editas Medicine Gene Therapy in Oncology Introduction13.8.4 Editas Medicine Revenue in Gene Therapy in Oncology Business (2015-2020)13.8.5 Editas Medicine Recent Development13.9 Geron Corp13.9.1 Geron Corp Company Details13.9.2 Geron Corp Business Overview and Its Total Revenue13.9.3 Geron Corp Gene Therapy in Oncology Introduction13.9.4 Geron Corp Revenue in Gene Therapy in Oncology Business (2015-2020)13.9.5 Geron Corp Recent Development13.10 Idera Pharmaceuticals13.10.1 Idera Pharmaceuticals Company Details13.10.2 Idera Pharmaceuticals Business Overview and Its Total Revenue13.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Introduction13.10.4 Idera Pharmaceuticals Revenue in Gene Therapy in Oncology Business (2015-2020)13.10.5 Idera Pharmaceuticals Recent Development13.11 Intellia Therapeutics10.11.1 Intellia Therapeutics Company Details10.11.2 Intellia Therapeutics Business Overview and Its Total Revenue10.11.3 Intellia Therapeutics Gene Therapy in Oncology Introduction10.11.4 Intellia Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)10.11.5 Intellia Therapeutics Recent Development13.12 Johnson & Johnson10.12.1 Johnson & Johnson Company Details10.12.2 Johnson & Johnson Business Overview and Its Total Revenue10.12.3 Johnson & Johnson Gene Therapy in Oncology Introduction10.12.4 Johnson & Johnson Revenue in Gene Therapy in Oncology Business (2015-2020)10.12.5 Johnson & Johnson Recent Development13.13 Marsala Biotech10.13.1 Marsala Biotech Company Details10.13.2 Marsala Biotech Business Overview and Its Total Revenue10.13.3 Marsala Biotech Gene Therapy in Oncology Introduction10.13.4 Marsala Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)10.13.5 Marsala Biotech Recent Development13.14 Merck10.14.1 Merck Company Details10.14.2 Merck Business Overview and Its Total Revenue10.14.3 Merck Gene Therapy in Oncology Introduction10.14.4 Merck Revenue in Gene Therapy in Oncology Business (2015-2020)10.14.5 Merck Recent Development13.15 Mologen AG10.15.1 Mologen AG Company Details10.15.2 Mologen AG Business Overview and Its Total Revenue10.15.3 Mologen AG Gene Therapy in Oncology Introduction10.15.4 Mologen AG Revenue in Gene Therapy in Oncology Business (2015-2020)10.15.5 Mologen AG Recent Development13.16 Oncolytics Biotech10.16.1 Oncolytics Biotech Company Details10.16.2 Oncolytics Biotech Business Overview and Its Total Revenue10.16.3 Oncolytics Biotech Gene Therapy in Oncology Introduction10.16.4 Oncolytics Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)10.16.5 Oncolytics Biotech Recent Development13.17 Oncosec10.17.1 Oncosec Company Details10.17.2 Oncosec Business Overview and Its Total Revenue10.17.3 Oncosec Gene Therapy in Oncology Introduction10.17.4 Oncosec Revenue in Gene Therapy in Oncology Business (2015-2020)10.17.5 Oncosec Recent Development13.18 Oncotelic10.18.1 Oncotelic Company Details10.18.2 Oncotelic Business Overview and Its Total Revenue10.18.3 Oncotelic Gene Therapy in Oncology Introduction10.18.4 Oncotelic Revenue in Gene Therapy in Oncology Business (2015-2020)10.18.5 Oncotelic Recent Development13.19 Shenzhen SiBiono GeneTech10.19.1 Shenzhen SiBiono GeneTech Company Details10.19.2 Shenzhen SiBiono GeneTech Business Overview and Its Total Revenue10.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Introduction10.19.4 Shenzhen SiBiono GeneTech Revenue in Gene Therapy in Oncology Business (2015-2020)10.19.5 Shenzhen SiBiono GeneTech Recent Development13.20 Sillajen Biotherapeutics10.20.1 Sillajen Biotherapeutics Company Details10.20.2 Sillajen Biotherapeutics Business Overview and Its Total Revenue10.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Introduction10.20.4 Sillajen Biotherapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)10.20.5 Sillajen Biotherapeutics Recent Development13.21 Tocagen10.21.1 Tocagen Company Details10.21.2 Tocagen Business Overview and Its Total Revenue10.21.3 Tocagen Gene Therapy in Oncology Introduction10.21.4 Tocagen Revenue in Gene Therapy in Oncology Business (2015-2020)10.21.5 Tocagen Recent Development13.22 UniQure10.22.1 UniQure Company Details10.22.2 UniQure Business Overview and Its Total Revenue10.22.3 UniQure Gene Therapy in Oncology Introduction10.22.4 UniQure Revenue in Gene Therapy in Oncology Business (2015-2020)10.22.5 UniQure Recent Development13.23 Ziopharm Oncology10.23.1 Ziopharm Oncology Company Details10.23.2 Ziopharm Oncology Business Overview and Its Total Revenue10.23.3 Ziopharm Oncology Gene Therapy in Oncology Introduction10.23.4 Ziopharm Oncology Revenue in Gene Therapy in Oncology Business (2015-2020)10.23.5 Ziopharm Oncology Recent Development

14 Analysts Viewpoints/Conclusions

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

Download Full Report https://www.qyresearchmedical.com/report/checkout/57077/3500

Contact Us:

QYResearch Medical

URL http://www.qyresearchmedical.com/

Mailing Address : Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Any Assistance, Email [emailprotected]

See more here:
Gene Therapy in Oncology Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis with...

Recommendation and review posted by Bethany Smith

Gene Therapy Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Gene Therapy Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Gene Therapy industry. Both established and new players in Gene Therapy industries can use the report to understand the Gene Therapy market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857391

Analysis of the Market:

Gene therapy is an experimental treatment that involves introducing genetic material into a persons cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinsons disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a vector. The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.

Gene therapy is a method that involves introducing genetic material into a persons cells to fight or prevent diseases. In recent decades of years, researchers are paying more and more attention on it. Until today, it is still in infancy. There are many bio-technology companies entered into this market and carry on related research and development.

These research companies are including Bluebird Bio, Sangamom, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical and Advantagene. Among them, the top 5 research companies occupied more than 85% market.

Generally, the research fees of companies are come from their collaboration partners. For example, Bayer Healthcare is the partner of Dimension Therapeutics. General, some products of these companies are in the period 3 of their pipeline.

In general, cancer diseases are still the largest application with market share over 65% in 2015. In addition, there are some companies are focus on rare diseases.

Market Analysis and Insights: Global Gene Therapy Market

In 2019, the global Gene Therapy market is valued at considerable rate by the end of 2026, growing at a steady rate of CAGR during 2021-2026.

Global Gene Therapy Scope and Market Size

Gene Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gene Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Gene Therapy market is segmented into Ex vivo, In Vivo, etc.

Segment by Application, the Gene Therapy market is segmented into Cancer, Monogenic, Infectious disease, Cardiovascular disease, Other, etc.

Regional and Country-level Analysis

The Gene Therapy market is analysed and market size information is provided by regions (countries).

The key regions covered in the Gene Therapy market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape and Gene Therapy Market Share Analysis

Gene Therapy market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Gene Therapy business, the date to enter into the Gene Therapy market, Gene Therapy product introduction, recent developments, etc.

The major vendors include Bluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene, etc.

This report focuses on the global Gene Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Gene Therapy Market Breakdown by Types:

s

Gene Therapy Market Breakdown by Application:

Critical highlights covered in the Global Gene Therapy market include:

The information available in the Gene Therapy Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Gene Therapy Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14857391

Reasons for Buy Gene Therapy Market Report:

In the end, Gene Therapy Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Asphalt Modifiers Market Size 2020 research Reports collect information useful for the extensive, technical, market-oriented, commercial study Future Growth by 2026

Global MEMS Accelerometer for Consumer Electronics Market Size 2020 define, describe, and technology, application, end user, region, commercial study Future Growth by 2026

Global EVAR Stent Grafts Market Size 2020 research Reports collect information useful for the extensive, technical, market-oriented, commercial study Future Growth by 2026

Global Carbon Steel Tubing in Oil and Gas Lift Applications Market 2020: Industry Trends and Investigation Growth Rate, consumption by Regional data, Product & Application Segmentation, Key Companies and Analysis By 2026

Global In-Car Entertainment (Infotainment) (ICE) Systems Market 2020: Industry Trends and Investigation Growth Rate, consumption by Regional data, Product & Application Segmentation, Key Companies and Analysis By 2026

Chains and Sprockets in Material Handling Equipment Market 2020 Growth Analysis, Share, and consumption by Regional data, Investigation and Growth, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2024

Global Regenerative Desiccant Dryers Market Size 2020 research Reports collect information useful for the extensive, technical, market-oriented, commercial study Future Growth by 2026

Global Synbiotic Foods Market Size 2020 Trend and Opportunities, Market Share, Analysis, CAGR and Value Chain Study, Showing Impressive Growth by 2024

Global Audience Targeting Software Market 2020 to Expand at a CAGR of by 2026: Analysis by Top Manufacturers, Product Type, Market Size & Growth, Focused Application

Read more:
Gene Therapy Market 2020 to Flourish with an Impressive CAGR of XX% in the year 2026, Predicts Market Research Future According to Current Market...

Recommendation and review posted by Bethany Smith

TipRanks

Expectations of good news on the near horizon are buoying markets right now. Over the past month, both the S&P 500 and the NASDAQ are up 11% to new record highs.Investors are excited at the prospect of a COVID vaccine coming before the winter is out. And the electoral results, that Democrat Joe Biden will ascend to the Presidency while the Republicans will emerge strengthened in Congress, promise the avoidance of extremes typical of divided government. In short, investors are looking forward to return to normal environment over the next several months. And that has them seeking stocks that are primed for gains. Against this backdrop, Goldman Sachs analysts are pounding the table on three stocks in particular, noting that each could surge over 40% in the year ahead. After running both tickers through TipRanks database, we found out that the rest of the Street is also standing squarely in the bull camp.Codiack BioSciences (CDAK)As we have all learned from coronavirus pandemic, some new thing in medical science can make huge impact on our world. Codiack aims to turn that principle to good. This research-oriented pharmaceutical aims to turn exosome therapeutics into a whole new class of medicines. Exosomes are the degradation mechanism RNA, and can transfer genetic material around a body.And therein lies the potential. Codiack has developed a design platform for the engineering of exosome proteins capable of carrying and protecting drug molecules through cell walls. In effect, the proteins will mimic the pathways used by viruses but are non-viral, and are designed to carry a payload of therapeutic agents. If successful, exosome therapy offers doctors the ability to design a drug that will deliver specific agents to specific cells to fight specific disease.Codiack is involved in all aspects of exosome therapeutics, from design to manufacturing, and currently has an active pipeline of agents seven, in all in various stages of discovery, preclinical testing, and the beginnings of Phase 1 trials.In the biosciences, success or failure is all about that pipeline, and in its diverse, active pipeline of agents in a new sector of biotechnological pharmaceuticals, Codiack has a fine resource to attract investors. To get those investors, the company went public this past October, selling 5.5 million shares at an opening price of $14.10 per share.Among the healthcare name's fans is Goldman Sachs analyst Graig Suvannavejh. The analyst wrote, Biopharma industry interest in exosomes has long been high, but engineering them for a specific function and manufacturing at scale have both proven challenging. Among a field of multiple competitors, CDAK has made the most significant progress on both fronts, and as such we view their technology platform as best-in-class."Given share underperformance (-37%) since the IPO, we find risk/reward highly compelling at current levels, and with key 2021 data sets to provide potential de-risking and positive share inflection," the analyst concluded.Suvannavejh rates CDAK a Buy, and his $29 price target shows the extent of his confidence it implies a 222% upside for the coming year. (To watch Suvannavejhs track record, click here)Overall, Codiack has a Strong Buy from the analyst consensus 3 reviewers have put up Buy ratings in recent weeks. The stock is selling for $8.90, and its $24 average price target implies a 166% one-year upside potential. (See CDAK stock analysis on TipRanks)Arcutis Biotherapeutics (ARQT)Acrutis is a pioneering researcher in the treatment of dermatological disease. Arcutis is involved in discovering the next generation of dermatological treatments an important niche, especially when one realizes that one common ailment, psoriasis, has not seen an FDA approval for a novel treatment in over two decades.The company is leveraging recent advances in immunology and inflammation to find new approaches to skin treatment. The goal is to make it easier for patients and doctors together to manage conditions like psoriasis, alopecia, atopic dermatitis, seborrheic dermatitis, and vitiligo, to name just a few.The company's lead candidate, ARQ-151 (roflumilast cream), is about to enter a phase 3 trial for atopic dermatitis, and is in an advanced phase 3 stage in Plaque Psoriasis. Arcutis has recently issued an update on positive data from the Phase 2 trials of ARQ-151 in atopic dermatitis. The drug is a once-daily treatment, and has demonstrated significant patient relief from symptoms, especially itching and itching-related sleep problems. This is another stock in Suvannavejhs coverage universe. The Goldman analyst is impressed by developments in the companys pipeline work, noting: ARQT provided an update on the outcome of its end-of-Phase 2 meetings with the FDA, following their Phase 2a trial of ARQ-151 in atopic dermatitis (AtD). Feedback from regulators was broadly encouraging, in particular, acknowledging the robust long-term safety data being generated by ARQT for ARQ-151 in plaque psoriasisAccordingly, Suvannavejh rates ARQT a Buy, and sets a $36 price target that indicates room for 40% upside growth in 2021. (To watch Suvannavejhs track record, click here)Arcutis has 2 recent Buy reviews, making the consensus rating a Moderate Buy. The stocks average price target is $37, suggesting a 44% upside from current levels. (See ARQT stock analysis on TipRanks)Oak Street Health (OSH)With the last stock, we move from medical research to medical care. Specifically, Oak Street Health is a primary care clinic operator, and part of the Medicare Network. The company has operations and clinics in Illinois, Indiana, Michigan, Pennsylvania, and Ohio, along with New York, North Carolina, Rhode Island, Tennessee, and Texas. It has been in operation for eight years, and went public this past summer, holding the IPO in August.In the third quarter, the companys first as a publicly traded entity, OSH brought in $217.9 million in revenue. The revenue number was up 56% from the year-ago quarter. Earnings per share matched expectations, at 15 cents.The companys expansion proceeds apace, and in October, Oak Street entered New York by opening, in Brooklyn, its 70th location. A planned expansion in Texas, involving a partnership with Walmart, is also proceeding as planned, and Oak Street has opened its first Walmart Community Clinic the Dallas-Fort Worth area city of Carrollton.Robert Jones, covering this stock for Goldman, set a $74 price target to back his Buy rating. At currently levels, this target implies an upside of ~58% in the next 12 months. (To watch Jones track record, click here)Results suggest operations are still on track, with few incremental updates since the 2Q call, where management noted a resumption of center openings, (pivoted) marketing efforts, and in-person visits despite COVID. In 3Q, OSH opened 13 new centers and is on track for 73-75 by end of year The company maintained that it is continuing to operate at a high level in places with elevated COVID case counts like Chicago and Detroit, Jones noted.All in all, the Strong Buy analyst consensus rating OSH is based on 8 reviews, breaking down to 7 Buys and just a single Hold. The stock is selling for $46.94, and its $61.29 average price target suggests it has a ~31% upside for the coming year. (See OSH stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read the original here:
Global Contract Cell and Gene Therapy Manufacturing Market Report 2020-2026: CDMO Categorization - Primed for Business Model Disruption - Yahoo...

Recommendation and review posted by Bethany Smith

The Most Recent study on the Hemophilia Gene Therapy Market Research provides a profound comprehension of the various market dynamics like trends, drivers, the challenges, and opportunities. The report further elaborates on the micro and macro-economic elements that are predicted to shape the increase of the Hemophilia Gene Therapy market throughout the forecast period (2019-2029).

The introduced study elucidates the crucial indicators of Market growth which comes with a thorough analysis of this value chain, CAGR development, and Porters Five Forces Analysis. This data may enable readers to understand the quantitative growth parameters of this international industry that is Hemophilia Gene Therapy .

Analytical Insights Included from the Hemophilia Gene Therapy Market Report

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3107

Hemophilia Gene Therapy Market Segmentation Assessment

The increase prospects of this market in various Regions are studied in the report together with details like the regulatory framework, political, and financial outlook of each region.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3107

The COVID-19 pandemic has changed narratives related to growth and expansion across several key industries. Therefore, theHemophilia Gene Therapy market is also battling the cons of supply chain disruptions and procurement issues. Over the course of the next quarter, market players could be investing in new technologies to recover from the shocks of the pandemic.

The report provides a comprehensive account of the following key points:

The report also answers some of the burning questions pertaining to market expansion:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3107

The Report intends to eliminate the subsequent doubts regarding the Hemophilia Gene Therapy market:

Reasons To Choose Fact.MR:

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email:[emailprotected]

Web:https://www.factmr.com/

Read the original post:
Hemophilia Gene Therapy Market to Develop Rapidly by 2018 to 2028 - The Haitian-Caribbean News Network

Recommendation and review posted by Bethany Smith

Pune, India, Nov. 26, 2020 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market size is predicted to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. The growing cases of rare diseases can be critical factor in fueling the demand for mucopolysaccharidosis treatment, which in turn, will aid the expansion of the market. The market in North America generated a revenue of USD 1,019.4 million in 2018. The growth in the region is attributed to the higher diagnosis and treatment rates for a number of rare disorders.

KEY INDUSTRY DEVELOPMENTS:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/mucopolysaccharidosis-treatment-market-102551

Unmet Clinical Needs to Influence Market Growth

The growing necessity for advanced therapeutics will impel companies to launch novel therapies, which in turn, will boost the mucopolysaccharidosis treatment market growth in the forthcoming years. Moreover, the growing unmet clinical needs of patients along with better treatment outcomes will spur demand for mucopolysaccharidosis treatment market during the forecast period.

Moreover, the increasing acquisitions and deals between key players will bolster healthy growth of the market. For instance, in April 2019, GC Pharma announced the signing of a licensing deal with Clinigen KK in Japan for their product offering of Hunterase ICV, which is used for the treatment of Mucopolysaccharidosis Type II (Hunter syndrome).

In addition, the increasing R&D by pharmaceutical companies for the mass production of conventional medications or therapies to treat diseases such as heart disease and diabetes along with rare disorders such as the types of mucopolysaccharidosis. This factor will aid the mucopolysaccharidosis treatment market revenue in the foreseeable future.

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/mucopolysaccharidosis-treatment-market-102551

Increasing Prevalence of Rare Diseases to Stimulate Growth in North America

The market in North America generated a revenue of USD 1,019.4 million in 2018. The growth in the region is attributed to the higher diagnosis and treatment rates for a number of rare disorders. The favorable reimbursement policies for such therapies will also have a weighty impact on the market in North America.

The rising awareness among patient population towards advanced treatment options will also spur demand for mucopolysaccharidosis treatment market. The presence of significant players and biopharmaceutical companies along with ongoing clinical trials will further augment growth in North America. Europe is predicted to witness high growth during the forecast period owing to the high sales of Elaprase and ALDURAZYME in the region.

Asia Pacific is predicted to grow significantly due to launch of novel therapeutics such as Hunterase in Japan. The growing patient population in various countries will enable growth of the market in the region.

Quick Buy - Mucopolysaccharidosis Treatment Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102551

The Report Lists the Key Companies in the Mucopolysaccharidosis Treatment Market

Global Mucopolysaccharidosis Treatment Market Segmentations:

By Treatment

Enzyme Replacement Therapy (ERT)

Others

By Disease Type

Mucopolysaccharidosis Type I

Mucopolysaccharidosis Type II

Mucopolysaccharidosis Type IV A

Mucopolysaccharidosis Type VI

Others

By Route of Administration

Intravenous

Intracerebroventricular (ICV)

By End User

Hospitals

Specialty Clinics

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)

Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)

Rest of the World

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/mucopolysaccharidosis-treatment-market-102551

SECONDARY DATA SOURCES THAT WE REFER TO:

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/mucopolysaccharidosis-treatment-market-102551

Have a Look at Related Reports:

Injectable Drug Delivery Market Share and Global Trend By Device Type (Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors, Others), By Application (Autoimmune Disorders, Diabetes, Pain Management, Aesthetic Treatments, Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, Others), By End-User (Hospitals, Home Care Settings, Clinics, Others) and Geography Forecast till 2026

Psoriasis Treatment Market Share and Global Trend By Drug Class (TNF Inhibitors, Interleukins, Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies), and Geography Forecast till 2026

Medical Lasers Market Share and Global Trend By Type (Surgical Lasers, Dental Lasers, Aesthetic Lasers, Others), By Product (Laser Systems, Consumables), By End User (Hospitals, Specialty Clinics) and Geography Forecast till 2026

Telehealth Market Share and Global Trend By Type (Products, Services), By Application (Telemedicine, Patient Monitoring, Continuous Medical Education, Others), By Modality (Store-and-forward (Asynchronous), Real-time (Synchronous), Remote Patient Monitoring), By End User (Healthcare Facilities, Homecare, Others), and Geography Forecast till 2026

Clear Aligners Market Share and Global Trend By Patient Age Group (Teenager, Adults), By End-User (Hospitals, Dental & Orthodontic Clinics) and Geography Forecast till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/mucopolysaccharidosis-treatment-market-9710

Read the original post:
Mucopolysaccharidosis Treatment Market to Exhibit a CAGR of 10.4% and Hit USD 4.37 Billion by 2026; Growing Cases of Rare Diseases to Spur Business...

Recommendation and review posted by Bethany Smith